<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        69-892-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ENBREL 50MG PRE-FILLED PEN
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ETANERCEPT
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3368.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pfizer Manufacturing Belgium N.V." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pfizer Manufacturing Belgium N.V.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2657]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Pfizer Saudi Trading
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            PFIZER SAUDI LIMITED
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AB01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Enbrel is a medicine that is made from two human proteins. It blocks the activity of another protein in the body that causes inflammation. Enbrel works by reducing the inflammation associated with certain diseases.</p><p>&nbsp;</p><p>In adults (aged 18 and over), Enbrel can be used for moderate or severe <strong>rheumatoid arthritis</strong>, <strong>psoriatic arthritis</strong>, severe<strong> axial spondyloarthritis</strong> including<strong> ankylosing spondylitis,</strong> <strong>and non-radiographic axial spondyloarthritis,</strong> and moderate or severe <strong>psoriasis</strong> &ndash; in each case usually when other widely used treatments have not worked well enough or are not suitable for you.</p><p>&nbsp;</p><p>For rheumatoid arthritis, Enbrel is usually used in combination with methotrexate, although it may also be used alone if treatment with methotrexate is unsuitable for you. Whether used alone or in combination with methotrexate, Enbrel can slow down the damage to your joints caused by the rheumatoid arthritis and improve your ability to do normal daily activities.</p><p>&nbsp;</p><p>For psoriatic arthritis patients with multiple joint involvement, Enbrel can improve your ability to do normal daily activities. For patients with multiple symmetrical painful or swollen joints (e.g., hands, wrists and feet), Enbrel can slow down the structural damage to those joints caused by the disease.</p><p>&nbsp;</p><p>Enbrel is also prescribed for the treatment of the following diseases in children and adolescents</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; For the following types of juvenile idiopathic arthritis when treatment with methotrexate has not worked well enough or is not suitable for them:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in patients from the age of 2 years</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Psoriatic arthritis in patients from the age of 12 years</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For enthesitis-related arthritis in patients from the age of 12 years when other widely used treatments have not worked well enough or are not suitable for them</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe psoriasis in patients from the age of 6 years who have had an inadequate response to (or are unable to take) phototherapies or other systemic therapies.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Enbrel</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you, or the child you are caring for, are allergic to etanercept or any of the other ingredients of Enbrel (listed in section 6). If you or the child experience allergic reactions such as chest tightness, wheezing, dizziness or rash, do not inject more Enbrel, and contact your doctor immediately.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you or the child have, or are at risk of developing a serious blood infection called sepsis. If you are not sure, please contact your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you or the child have an infection of any kind. If you are not sure, please talk to your doctor.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>&nbsp;</p><p>Talk to your doctor before taking Enbrel.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Allergic reactions:</strong> If you or the child experience allergic reactions such as chest tightness, wheezing, dizziness or rash, do not inject more Enbrel, and contact your doctor immediately.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Infections/surgery:</strong> If you or the child develop a new infection, or are about to have any major surgery, your doctor may wish to monitor the treatment with Enbrel.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Infections/diabetes:</strong> Tell your doctor if you or the child have a history of recurrent infections or suffer from diabetes or other conditions that increase the risk of infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Infections/monitoring: </strong>Tell your doctor of any recent travel outside the European region. If you or the child develop symptoms of an infection such as fever, chills or cough, notify your doctor immediately. Your doctor may decide to continue to monitor you or the child for the presence of infections after you or the child stop using Enbrel.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Tuberculosis: </strong>As cases of tuberculosis have been reported in patients treated with Enbrel, your doctor will check for signs and symptoms of tuberculosis before starting Enbrel. This may include a thorough medical history, a chest X-ray and a tuberculin test. The conduct of these tests should be recorded on the Patient Card. It is very important that you tell your doctor if you or the child have ever had tuberculosis, or have been in close contact with someone who has had tuberculosis. If symptoms of tuberculosis (such as persistent cough, weight loss, listlessness, mild fever), or any other infection appear during or after therapy, tell your doctor immediately.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hepatitis B: </strong>Tell your doctor if you or the child have or have ever had hepatitis B.<strong> </strong>Your doctor should test for the presence of hepatitis B infection before you or the child begin treatment with Enbrel. Treatment with Enbrel may result in reactivation of hepatitis B in patients who have previously been infected with the hepatitis B virus. If this occurs, you should stop using Enbrel.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hepatitis C:</strong> Tell your doctor if you or the child have hepatitis C. Your doctor may wish to monitor the treatment with Enbrel in case the infection worsens.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Blood disorders:</strong> Seek medical advice immediately if you or the child have any signs or symptoms such as persistent fever, sore throat, bruising, bleeding or paleness. Such symptoms may point to the existence of potentially life-threatening blood disorders, which may require discontinuation of Enbrel.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Nervous system and eye disorders:</strong> Tell your doctor if you or the child have multiple sclerosis, optic neuritis (inflammation of the nerves of the eyes) or transverse myelitis (inflammation of the spinal cord). Your doctor will determine if Enbrel is an appropriate treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Congestive heart failure:</strong> Tell your doctor if you or the child have a history of congestive heart failure, because Enbrel needs to be used with caution under these circumstances.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Cancer: </strong>Tell your doctor if you have or have ever had lymphoma (a type of blood cancer) or any other cancer before you are given Enbrel.</p><p>Patients with severe rheumatoid arthritis, who have had the disease for a long time, may be at higher than average risk of developing lymphoma.</p><p>Children and adults taking Enbrel may have an increased risk of developing lymphoma or another cancer.</p><p>Some children and teenage patients who have received Enbrel or other medicines that work the same way as Enbrel have developed cancers, including unusual types, which sometimes resulted in death.</p><p>Some patients receiving Enbrel have developed skin cancers.&nbsp;Tell your doctor if you or the child develop any change in the appearance of the skin or growths on the skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Chickenpox:</strong> Tell your doctor if you or the child are exposed to chickenpox when using Enbrel. Your doctor will determine if preventive treatment for chickenpox is appropriate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Latex: </strong>The needle cap of the MYCLIC pen is made from latex (dry natural rubber). Contact your doctor before using Enbrel if the needle cap will be handled by, or Enbrel will be given to, someone with a known or possible hypersensitivity (allergy) to latex.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Alcohol abuse:</strong> Enbrel should not be used for the treatment of hepatitis related to alcohol abuse. Please tell your doctor if you or the child in your care have a history of alcohol abuse.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Wegener&rsquo;s granulomatosis:</strong> Enbrel is not recommended for the treatment of Wegener&rsquo;s granulomatosis, a rare inflammatory disease. If you or the child in your care have Wegener&rsquo;s granulomatosis, talk to your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Anti-diabetic medicines:</strong> Tell your doctor if you or the child have diabetes or are taking medicines to treat diabetes. Your doctor may decide if you or the child need less anti-diabetic medicine while taking Enbrel.</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents </strong></p><p>&nbsp;</p><p><strong>Vaccinations:</strong> If possible, children should be up to date with all vaccinations before using Enbrel. Some vaccines, such as oral polio vaccine, should not be given while using Enbrel. Please consult your doctor before you or the child receive any vaccines.</p><p><strong>&nbsp;</strong></p><p>Enbrel should not normally be used in children with polyarthritis or extended oligoarthritis below the age of 2 years, or in children with enthesitis-related arthritis or psoriatic arthritis below the age of 12 years, or in children with psoriasis below the age of 6 years.</p><p><strong>&nbsp;</strong></p><p>Other medicines and Enbrel</p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you or the child are taking, have recently taken or might take any other medicines (including anakinra, abatacept or sulfasalazine), even those not prescribed by the doctor. You or the child should not use Enbrel with medicines that contain the active substance anakinra or abatacept.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding</p><p>&nbsp;</p><p>Enbrel should only be used during pregnancy if clearly needed. You should consult your doctor if you become pregnant, think you may be pregnant, or are planning to have a baby.</p><p>&nbsp;</p><p>If you received Enbrel during pregnancy, your baby may have a higher risk of getting an infection. In addition, one study found more birth defects when the mother had received Enbrel in pregnancy, compared with mothers who had not received Enbrel or other similar medicines (TNF‑antagonists), but there was no particular kind of birth defect reported. Another study found no increased risk of birth defects when the mother had received Enbrel in pregnancy. Your doctor will help you to decide whether the benefits of treatment outweigh the potential risk to your baby.</p><p>&nbsp;</p><p>Talk to your doctor if you want to breastfeed while on Enbrel treatment. It is important that you tell your baby&rsquo;s doctors and other healthcare professionals about the use of Enbrel during pregnancy and breastfeeding before your baby receives any vaccine.</p><p>&nbsp;</p><p>Driving and using machines</p><p>&nbsp;</p><p>The use of Enbrel is not expected to affect the ability to drive or use machines.</p><p>&nbsp;</p><p>Enbrel contains sodium</p><p>&nbsp;</p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dosage unit, that is to say essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor if or pharmacist you are not sure.</p><p>&nbsp;</p><p>If you feel that the effect of Enbrel is too strong or too weak, talk to your doctor or pharmacist.</p><p>&nbsp;</p><p>You have been prescribed a 50&nbsp;mg strength of Enbrel. A 25&nbsp;mg strength of Enbrel is available for doses of 25&nbsp;mg.</p><p>&nbsp;</p><p>Dosing for adult patients (aged 18 years or over)</p><p>&nbsp;</p><p><u>Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis including ankylosing spondylitis</u></p><p>&nbsp;</p><p>The usual dose is 25&nbsp;mg given twice a week or 50&nbsp;mg once a week as an injection under the skin. However, your doctor may determine an alternative frequency at which to inject Enbrel.</p><p>&nbsp;</p><p><u>Plaque psoriasis</u></p><p>&nbsp;</p><p>The usual dose is 25&nbsp;mg twice a week or 50&nbsp;mg once a week.&nbsp;</p><p>&nbsp;</p><p>Alternatively, 50&nbsp;mg may be given twice a week for up to 12 weeks, followed by 25&nbsp;mg twice a week or 50&nbsp;mg once a week.</p><p>&nbsp;</p><p>Your doctor will decide how long you should take Enbrel and whether retreatment is needed based on your response. If Enbrel has no effect on your condition after 12 weeks, your doctor may tell you to stop taking this medicine.</p><p>&nbsp;</p><p>Use in children and adolescents</p><p>&nbsp;</p><p>The appropriate dose and frequency of dosing for the child or adolescent will depend on body weight and disease. Your doctor will determine the correct dose for the child and will prescribe an appropriate strength of Enbrel (10&nbsp;mg, 25&nbsp;mg or 50&nbsp;mg).</p><p>&nbsp;</p><p>For polyarthritis or extended oligoarthritis in patients from the age of 2 years, or enthesitis-related arthritis or psoriatic arthritis in patients from the age of 12 years, the usual dose is 0.4&nbsp;mg of Enbrel per kg bodyweight (up to a maximum of 25&nbsp;mg) given twice weekly, or 0.8&nbsp;mg of Enbrel per kg of bodyweight (up to a maximum of 50&nbsp;mg) given once weekly.</p><p>&nbsp;</p><p>For psoriasis in patients from the age of 6 years, the usual dose is 0.8&nbsp;mg of Enbrel per kg bodyweight (up to a maximum of 50&nbsp;mg), and should be given once weekly. If Enbrel has no effect on the child&rsquo;s condition after 12 weeks, your doctor may tell you to stop using this medicine.</p><p>&nbsp;</p><p>The doctor will provide you with detailed directions for preparing and measuring the appropriate dose.</p><p>&nbsp;</p><p>Method and route of administration</p><p>&nbsp;</p><p>Enbrel is administered by an injection under the skin (by subcutaneous injection).</p><p>&nbsp;</p><p>Enbrel can be taken with or without food or drink.</p><p>&nbsp;</p><p><strong>Detailed instructions on how to inject Enbrel are provided in section 7</strong><strong> &ldquo;Instructions for use&rdquo;.</strong><strong> </strong>Do not mix the Enbrel solution with any other medicine.</p><p>&nbsp;</p><p>To help you remember, it may be helpful to write in a diary which day(s) of the week Enbrel should be used.</p><p>&nbsp;</p><p>If you use more Enbrel than you should</p><p><strong>&nbsp;</strong></p><p>If you have used more Enbrel than you should (either by injecting too much on a single occasion or by using it too frequently), talk to a doctor or pharmacist immediately. Always have the outer carton of the medicine with you, even if it is empty.</p><p><strong>&nbsp;</strong></p><p>If you forget to inject Enbrel</p><p>&nbsp;</p><p>If you forget a dose, you should inject it as soon as you remember, unless the next scheduled dose is the next day; in which case you should skip the missed dose. Then continue to inject the medicine on the usual day(s). If you do not remember until the day that the next injection is due, do not take a double dose (two doses on the same day) to make up for a forgotten dose.</p><p>&nbsp;</p><p>If you stop using Enbrel</p><p>&nbsp;</p><p>Your symptoms may return upon discontinuation.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Allergic reactions</p><p>&nbsp;</p><p>If any of the following happen, do not inject more Enbrel. Tell your doctor immediately, or go to the casualty department at your nearest hospital.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Trouble swallowing or breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the face, throat, hands, or feet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling nervous or anxious, throbbing sensations, sudden reddening of the skin and/or a warm feeling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe rash, itching, or hives (elevated patches of red or pale skin that often itch)</p><p>&nbsp;</p><p>Serious allergic reactions are rare. However, any of the above symptoms may indicate an allergic reaction to Enbrel, so you should seek immediate medical attention.</p><p>&nbsp;</p><p>Serious side effects</p><p>&nbsp;</p><p>If you notice any of the following, you or the child may need urgent medical attention.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of <strong>serious infections</strong>, such as high fever that may be accompanied by cough, shortness of breath, chills, weakness, or a hot, red, tender, sore area on the skin or joints</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of <strong>blood disorders</strong>, such as bleeding, bruising, or paleness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of <strong>nerve disorders</strong>, such as numbness or tingling, changes in vision, eye pain, or onset of weakness in an arm or leg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of <strong>heart failure</strong> or <strong>worsening heart failure</strong>, such as fatigue or shortness of breath with activity, swelling in the ankles, a feeling of fullness in the neck or abdomen, night-time shortness of breath or coughing, bluish colour of the nails or the lips</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Signs of cancers: </strong>Cancers may affect any part of the body including the skin and blood, and possible signs will depend on the type and location of the cancer. These signs may include weight loss, fever, swelling (with or without pain), persistent cough, presence of lumps or growths on the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of <strong>autoimmune reactions</strong> (where antibodies are made that may harm normal tissues in the body) such as pain, itching, weakness, and abnormal breathing, thinking, sensation, or vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of lupus or lupus-like syndrome, such as weight changes, persistent rash, fever, joint or muscle pain, or fatigue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of <strong>inflammation of the blood vessels</strong> such as pain, fever, redness or warmth of the skin, or itching.</p><p>&nbsp;</p><p>These are rare or uncommon side effects, but are serious conditions (some of which may rarely be fatal). If these signs occur, tell your doctor immediately, or visit the casualty department at your nearest hospital.</p><p>&nbsp;</p><p>The known side effects of Enbrel include the following in groups of decreasing frequency:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Very common </strong>(may affect more than 1 in 10 people):</p><p>Infections (including colds, sinusitis, bronchitis, urinary tract infections and skin infections); injection site reactions (including bleeding, bruising, redness, itching, pain, and swelling) (these do not occur as often after the first month of treatment; some patients have developed a reaction at an injection site that was recently used); and headache.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Common </strong>(may affect up to 1 in 10 people):</p><p>Allergic reactions; fever; rash; itching; antibodies directed against normal tissue (autoantibody formation).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Uncommon </strong>(may affect up to 1 in 100 people):</p><p>Serious infections (including pneumonia, deep skin infections, joint infections, blood infection, and infections at various sites); worsening of congestive heart failure; low red blood cell count, low white blood cell count, low neutrophil (a type of white blood cell) count; low blood platelet count; skin cancer (excluding melanoma); localised swelling of the skin (angioedema); hives (elevated patches of red or pale skin that often itch); eye inflammation; psoriasis (new or worsening); inflammation of the blood vessels affecting multiple organs; elevated liver blood tests (in patients also receiving methotrexate treatment, the frequency of elevated liver blood tests is common); abdominal cramps and pain, diarrhoea, weight loss or blood in the stool (signs of bowel problems).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Rare </strong>(may affect up to 1 in 1,000 people):</p><p>Serious allergic reactions (including severe localised swelling of the skin and wheezing); lymphoma (a type of blood cancer); leukaemia (cancer affecting the blood and bone marrow); melanoma (a type of skin cancer); combined low platelet, red, and white blood cell count; nervous system disorders (with severe muscle weakness and signs and symptoms similar to those of multiple sclerosis or inflammation of the nerves of the eyes or spinal cord); tuberculosis; new onset congestive heart failure; seizures; lupus or lupus-like syndrome (symptoms may include persistent rash, fever, joint pain, and tiredness); skin rash, which may lead to severe blistering and peeling of the skin; lichenoid reactions (itchy reddish‑purple skin rash and/or threadlike white-grey lines on mucous membranes); inflammation of the liver caused by the body&#39;s own immune system (autoimmune hepatitis; in patients also receiving methotrexate treatment, the frequency is uncommon); immune disorder that can affect the lungs, skin and lymph nodes (sarcoidosis); inflammation or scarring of the lungs (in patients also receiving methotrexate treatment, the frequency of inflammation or scarring of the lungs is uncommon); damage to the tiny filters inside your kidneys leading to poor kidney function (glomerulonephritis).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Very rare </strong>(may affect up to 1 in 10,000 people): failure of the bone marrow to produce crucial blood cells.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Not known </strong>(frequency cannot be estimated from the available data): Merkel cell carcinoma (a type of skin cancer); Kaposi&rsquo;s sarcoma (a rare cancer related to infection with human herpes virus 8. Kaposi&rsquo;s sarcoma most commonly appear as purple lesions on the skin); excessive activation of white blood cells associated with inflammation (macrophage activation syndrome);&nbsp;recurrence of hepatitis B (a liver infection); worsening of a condition called dermatomyositis (muscle inflammation and weakness with an accompanying skin rash).</p><p>&nbsp;</p><p><strong>Additional side effects in children and adolescents</strong></p><p>&nbsp;</p><p>The side effects and their frequencies seen in children and adolescents are similar to those described above.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p><strong>&nbsp;</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To Report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance centre (NPC)</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and on the MYCLIC pre-filled pen after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg; &ndash; 8&deg;C). Do not freeze.</p><p>Keep the pre-filled pens in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>After taking a pre-filled pen from the refrigerator, <strong>wait approximately 15-30 minutes to allow the Enbrel solution</strong><strong> in the pen to reach room temperature</strong>. Do not warm in any other way.<strong> </strong>Immediate use is then recommended.&nbsp;</p><p>&nbsp;</p><p>Enbrel may be stored outside of the refrigerator at temperatures up to a maximum of 25&deg;C for a single period of up to four weeks; after which, it should not be refrigerated again. Enbrel should be discarded if not used within four weeks after removal from the refrigerator. It is recommended that you record the date that Enbrel is removed from the refrigerator and the date after which Enbrel should be discarded (no more than 4 weeks following the removal from the refrigerator).</p><p>&nbsp;</p><p>Inspect the solution in the pen by looking through the clear inspection window. The solution should be clear or slightly opalescent, colourless or pale yellow, and may contain small white or almost transparent particles of protein. This appearance is normal for Enbrel. Do not use the solution if it is discoloured, cloudy, or if particles other than those described above are present. If you are concerned with the appearance of the solution, then contact your pharmacist for assistance.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance in Enbrel is etanercept. Each MYCLIC pre-filled pen contains 50&nbsp;mg of etanercept.&nbsp;</p><p>&nbsp;</p><p>The other ingredients are sucrose, sodium chloride, L-arginine hydrochloride, sodium phosphate monobasic dihydrate and sodium phosphate dibasic dihydrate, and water for injections.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Enbrel is supplied as a solution for injection in a pre-filled pen (MYCLIC) (solution for injection). The MYCLIC pen contains a clear, colourless or pale yellow solution for injection. Each pack contains 2, 4 or 12 pens and 2, 4 or 12 alcohol swabs. Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder</p><p>&nbsp;</p><p>Pfizer Saudi Limited, Saudi Arabia</p><p>&nbsp;</p><p><strong>Manufactured by</strong></p><p>&nbsp;</p><p>Pfizer Manufacturing Belgium NV, Puurs, Belgium</p><p>&nbsp;</p><p><strong>Packed &amp; Released by</strong></p><p>&nbsp;</p><p>Pfizer Saudi Limited, King Abdullah Economic City, Saudi Arabia</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                April 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">إنبريل هو دواء يتم تصنيعه من نوعين من البروتينات البشرية. وهو يحصر نشاط بروتين آخر في الجسم يسبب الالتهاب. ويعمل إنبريل عن طريق تقليل الالتهاب المصاحب لبعض الأمراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بالنسبة للبالغين (من سن ۱۸ عامًا فأكبر)، يمكن استخدام إنبريل لعلاج <strong>التهاب المفاصل الروماتويدي</strong> المتوسط أو الشديد، و<strong>التهاب المفاصل الصدفي</strong>، و<strong>التهاب المفاصل الفقاري المحوري </strong>الشديد بما في ذلك <strong>التهاب الفقار المقسط،</strong> <strong>والتهاب المفاصل الفقاري المحوري غير الظاهر بالتصوير الإشعاعي</strong>، وحالات <strong>الصدفية</strong> المتوسطة أو الشديدة - ويُستخدم عادةً في كل حالة إذا لم تكن العلاجات الأخرى شائعة الاستخدام فعالة بالقدر الكافي أو كانت غير مناسبة لحالتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بالنسبة لالتهاب المفاصل الروماتويدي، عادةً ما يستخدم إنبريل بالتزامن مع ميثوتريكسات، إلا أنه يمكن استخدامه بمفرده أيضًا إذا كان العلاج بميثوتريكسات ليس ملائمًا لحالتك. سواء استُخدم إنبريل بمفرده أو بالتزامن مع ميثوتريكسات، يمكنه أن يبطئ التلف الذي تتعرض له مفاصلك بسبب التهاب المفاصل الروماتويدي وأن يحسن من قدرتك على القيام بالأنشطة اليومية المعتادة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بالنسبة للمرضى المصابين بالتهاب المفاصل الصدفي مع تأثر عدة مفاصل، يمكن أن يحسن إنبريل من قدرتك على أداء الأنشطة اليومية المعتادة. وبالنسبة للمرضى الذين يعانون من ألم أو تورم في مفاصل متعددة متماثلة (على سبيل المثال، في اليدين والمعصمين والقدمين)، يمكن أن يبطئ إنبريل التلف البنيوي في تلك المفاصل الناتج عن المرض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ويمكن وصف إنبريل أيضًا لعلاج الأمراض التالية لدى الأطفال والمراهقين</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp; لعلاج الأنواع التالية من مرض التهاب المفاصل اليفعي مجهول السبب إذا لم يكن العلاج بميثوتريكسات فعالًا بالقدر الكافي أو لم يكن مناسبًا لحالة المرضى:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل المتعددة (سواء كان عامل الروماتويد إيجابيًا أو سلبيًا) والتهاب المفاصل القليلة الممتد لدى المرضى من سن عامين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل الصدفي لدى المرضى من سن ۱۲ عامًا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج التهاب المفاصل المتعلق بالتهاب الارتكاز لدى المرضى من سن ۱۲ عامًا إذا لم تكن العلاجات الأخرى شائعة الاستخدام فعالة بالقدر الكافي أو إذا لم تكن مناسبة لهم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج حالات الصدفية الشديدة لدى المرضى من سن ٦ أعوام ممن كانت استجابتهم غير ملائمة تجاه (أو لم يتمكنوا من تناول) العلاجات الضوئية أو العلاجات الجهازية الأخرى.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موانع استعمال إنبريل</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا أنت أو الطفل الذي ترعاه بالحساسية تجاه إيتانيرسيبت أو أي من المكونات الأخرى في إنبريل (المدرجة في قسم ٦). إذا أصبت أنت أو الطفل بتفاعلات حساسية مثل ضيق الصدر، أو الأزيز، أو الدوار، أو الطفح الجلدي، فلا تحقن أي كميات أخرى من إنبريل، واتصل بطبيبك في الحال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا أنت أو الطفل أو كنتما معرضين لخطر الإصابة بعدوى خطيرة في الدم تسمى إنتان الدم. إذا لم تكن متأكدًا، يرجى التواصل مع طبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا أنت أو الطفل بعدوى من أي نوع. إذا لم تكن متأكدًا، يرجى التحدث إلى طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاحتياطات عند استعمال إنبريل</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">تحدث إلى طبيبك قبل تناول إنبريل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تفاعلات الحساسية</strong>: إذا أصبت أنت أو الطفل بتفاعلات حساسية مثل ضيق الصدر، أو الأزيز، أو الدوار، أو الطفح الجلدي، فلا تحقن أي كميات أخرى من إنبريل، وتواصل مع طبيبك في الحال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>حالات العدوى/الجراحة</strong>: إذا أصبت أنت أو الطفل بعدوى جديدة، أو إذا كنتما على وشك الخضوع لأي جراحة كبرى، فقد يرغب طبيبك في مراقبة العلاج بإنبريل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>حالات العدوى/داء السكري:</strong> أخبر طبيبك إذا كان لديك أنت أو الطفل تاريخ من الإصابة بعدوى متكررة أو إذا كنتما تعانيان من داء السكري أو حالات أخرى تزيد من خطر حدوث العدوى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>حالات العدوى/المراقبة: أخبر طبيبك عن أي سفر</strong><strong> قمت به</strong><strong> مؤخرًا خارج </strong><strong>المنطقة الأوروبية.</strong> إذا أصبت أنت أو الطفل بأعراض عدوى مثل الحمى أو القشعريرة أو السعال، فأبلغ طبيبك فورًا. قد يقرر طبيبك استمرار مراقبة حالتك أو حالة الطفل لرصد حالات العدوى بعد أن تتوقف أنت أو الطفل عن استخدام إنبريل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>السل: </strong>نظرًا لأنه قد تم الإبلاغ عن حالات إصابة بالسل لدى المرضى الذين خضعوا للعلاج بإنبريل، سوف يتحقق طبيبك من وجود علامات وأعراض السل قبل بدء العلاج بإنبريل. يمكن أن يتضمن ذلك معرفة التاريخ الطبي بالكامل، وإجراء فحص بالأشعة السينية للصدر، وإجراء اختبار توبركولين. ينبغي تسجيل إجراء تلك الاختبارات في &quot;بطاقة المريض&quot;. من المهم للغاية أن تخبر طبيبك إذا سبق أن أصبت أنت أو الطفل بالسل، أو إذا خالطتما عن قرب شخصًا كان يعاني من السل. إذا ظهرت أعراض السل (مثل السعال المستمر، فقدان الوزن، الخمول، الحمى الخفيفة)، أو إذا ظهرت أي عدوى أخرى أثناء أو بعد العلاج، فأخبر طبيبك فورًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التهاب الكبد الوبائي </strong><strong>B</strong><strong>: </strong>أخبر طبيبك إذا كنت مصابًا أنت أو الطفل أو سبقت لكما الإصابة بالتهاب الكبد الوبائي B. ينبغي أن يجري طبيبك اختبارًا للكشف عن وجود عدوى التهاب الكبد الوبائي B قبل أن تبدأ أنت أو الطفل العلاج بإنبريل. قد ينتج عن العلاج بإنبريل إعادة تنشيط التهاب الكبد الوبائي B لدى المرضى الذين أصيبوا من قبل بفيروس التهاب الكبد الوبائي B. إذا حدث ذلك، يجب أن تتوقف عن استخدام إنبريل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التهاب الكبد الوبائي </strong><strong>C</strong><strong>:</strong> أخبر طبيبك إذا كنت مصابًا أنت أو الطفل بالتهاب الكبد الوبائي C. قد يرغب طبيبك في مراقبة العلاج بإنبريل في حالة تفاقم العدوى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>اضطرابات الدم:</strong> اطلب المشورة الطبية فورًا إذا أصبت أنت أو الطفل بأي علامات أو أعراض مثل الحمى المستمرة، أو احتقان الحلق، أو التكدم، أو النزيف، أو الشحوب. قد تشير مثل هذه الأعراض إلى وجود اضطرابات دم يُحتمل أن تكون مهددة للحياة، وقد يتطلب ذلك إيقاف إنبريل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>اضطرابات الجهاز العصبي والعينين:</strong> أخبر طبيبك إذا كنت مصابًا أنت أو الطفل بالتصلب المتعدد، أو التهاب العصب البصري (التهاب أعصاب العينين)، أو التهاب النخاع الشوكي المستعرض (التهاب الحبل الشوكي). سوف يحدد طبيبك إذا كان إنبريل علاجًا ملائمًا أم لا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>فشل القلب الاحتقاني:</strong> أخبر طبيبك إذا كان لديك أنت أو الطفل تاريخ من الإصابة بفشل القلب الاحتقاني، نظرًا لأنه ينبغي استخدام إنبريل بحذر في ظل تلك الظروف.</p><p dir="RTL"><strong>السرطان: </strong>أخبر طبيبك إذا كنت مصابًا أو سبق أن أصبت من قبل بسرطان الغدد الليمفاوية (أحد أنواع سرطان الدم) أو أي نوع آخر من السرطان قبل إعطائك إنبريل.</p><p dir="RTL">قد يكون المرضى المصابون بالتهاب المفاصل الروماتويدي الشديد، الذين أصيبوا بالمرض منذ فترة طويلة، معرضين لخطر الإصابة بسرطان الغدد الليمفاوية بدرجة أكبر من المتوسط.</p><p dir="RTL">قد يكون الأطفال والبالغون الذين يتناولون إنبريل أكثر عرضة للإصابة بسرطان الغدد الليمفاوية أو نوع آخر من السرطان.</p><p dir="RTL">بعض المرضى من الأطفال والمراهقين ممن تلقوا إنبريل أو أدوية أخرى تعمل بنفس طريقة إنبريل أصيبوا بالسرطانات، بما في ذلك الأنواع غير المعتادة، التي تسببت في الوفاة في بعض الأحيان.</p><p dir="RTL">أصيب بعض المرضى الذين تلقوا إنبريل بسرطانات الجلد. أخبر طبيبك إذا ظهر لديك أو لدى الطفل أي تغير في شكل الجلد أو أجزاء نامية على الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الجديري المائي:</strong> أخبر طبيبك إذا تعرضت أنت أو الطفل للجديري المائي عند استخدام إنبريل. سوف يحدد طبيبك إذا كان من الملائم تلقي علاج وقائي للجديري المائي أم لا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>اللاتكس: </strong>إن<strong> </strong>غطاء إبرة قلم MYCLIC مصنوع من اللاتكس (المطاط الطبيعي الجاف). اتصل بطبيبك قبل استخدام إنبريل إذا كان الشخص الذي سيتعامل مع غطاء الإبرة أو سيتلقى إنبريل شخصًا معروفًا بإصابته أو احتمال إصابته بفرط الحساسية تجاه اللاتكس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>سوء استخدام الكحوليات</strong>: يجب عدم استخدام إنبريل لعلاج التهاب الكبد الوبائي المتعلق بسوء استخدام الكحوليات. يرجى إخبار طبيبك إذا كان لديك أنت أو الطفل الذي ترعاه تاريخ من سوء استخدام الكحوليات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ورم فيجنر الحبيبي</strong>: لا يوصى باستخدام إنبريل لعلاج ورم فيجنر الحبيبي، وهو مرض التهابي نادر. إذا كنت مصابًا أنت أو الطفل الذي ترعاه بورم فيجنر الحبيبي، فتحدث إلى طبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الأدوية المضادة لداء السكري</strong>: أخبر طبيبك إذا كنت مصابًا أنت أو الطفل بداء السكري أو كنتما تتناولان أدوية لعلاج داء السكري. قد يقرر طبيبك إذا كان ينبغي عليك أو على الطفل تقليل جرعة الدواء المضاد لداء السكري أثناء تناول إنبريل أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اللقاحات:</strong> إذا أمكن، يجب إعطاء الأطفال آخر اللقاحات اللازمة في مواعيدها قبل استخدام إنبريل. ينبغي عدم إعطاء بعض اللقاحات، مثل لقاح شلل الأطفال الذي يؤخذ عن طريق الفم، أثناء استخدام إنبريل. ترجى استشارة طبيبك قبل أن تتلقى أنت أو الطفل أي لقاحات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عدم استخدام إنبريل عادةً مع الأطفال تحت سن عامين المصابين بالتهاب المفاصل المتعددة أو التهاب المفاصل القليلة الممتد، أو مع الأطفال المصابين بالتهاب المفاصل المتعلق بالتهاب الارتكاز أو التهاب المفاصل الصدفي البالغين من العمر أقل من ۱۲ عامًا، أو مع الأطفال المصابين بالصدفية تحت سن ٦ أعوام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أنت أو الطفل أو تناولتما مؤخرًا أو قد تتناولان أي أدوية أخرى (بما في ذلك أناكينرا، أو أباتاسيبت، أو سلفاسالازين)، حتى تلك الأدوية التي لم يصفها الطبيب. ينبغي ألا تستخدم أنت أو الطفل إنبريل مع أدوية تحتوي على المادة الفعالة أناكينرا أو أباتاسيبت.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">ينبغي عدم استخدام إنبريل أثناء الحمل إلّا إذا كانت هناك حاجة واضحة لذلك. ينبغي أن تستشيري طبيبكِ إذا أصبحتِ حاملًا أو كنتِ تعتقدين أنك قد تكونين حاملًا أو إذا كنتِ تخططين للحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تلقيتِ إنبريل أثناء الحمل، فقد يكون طفلكِ أكثر عرضة للإصابة بعدوى. بالإضافة إلى ذلك، وجدت إحدى الدراسات ارتفاعًا في نسبة العيوب الولادية عند تلقي الأم لإنبريل أثناء الحمل، مقارنة بالأمهات اللاتي لم يتلقين إنبريل أو أدوية أخرى مماثلة (مناهضات عامل نخر الورم)، ولكن لم يتم الإبلاغ عن نوع معين من العيوب الولادية. وجدت دراسة أخرى أنه لا يوجد ارتفاع في خطر حدوث العيوب الولادية عند تلقي الأم إنبريل أثناء الحمل. سيساعدكِ طبيبكِ في اتخاذ قرار بشأن ما إذا كانت فوائد العلاج تفوق الخطر المحتمل على طفلكِ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدثي إلى طبيبكِ إذا كنتِ ترغبين في الإرضاع أثناء العلاج بإنبريل. من المهم أن تخبري أطباء طفلكِ وغيرهم من أخصائيي الرعاية الصحية بشأن استخدام إنبريل أثناء الحمل والرضاعة الطبيعية قبل أن يتلقى طفلكِ أي لقاح.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير إنبريل على القيادة واستخدام الآلات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يتوقع أن يؤثر استخدام إنبريل على القدرة على القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات إنبريل</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>يحتوي إنبريل على الصوديوم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا الدواء على أقل من ۱ مليمول من الصوديوم (۲۳ ملجم) لكل وحدة جرعة، أي أنه &quot;خالٍ من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على استخدام هذا الدواء تمامًا كما أخبرك طبيبك. راجع طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا شعرت أن تأثير إنبريل أقوى من اللازم أو أضعف من اللازم، فتحدث إلى طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لقد وُصفت لك جرعة إنبريل بتركيز ٥۰ ملجم. هناك تركيز ۲٥ ملجم من إنبريل متاح للجرعات التي تبلغ ۲٥ ملجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جرعات المرضى من البالغين (في سن </strong><strong>۱۸</strong><strong> عامًا فأكثر)</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التهاب المفاصل الروماتويدي، والتهاب المفاصل الصدفي، والتهاب المفاصل الفقاري المحوري </u><u>بما في ذلك </u><u>التهاب الفقار المقسط</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة المعتادة هي ۲٥ ملجم تُعطى مرتين أسبوعيًا أو ٥۰ ملجم مرة واحدة أسبوعيًا في صورة حقنة تحت الجلد. بالرغم من ذلك، يمكن أن يحدد طبيبك معدلًا بديلًا لحقن إنبريل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الصدفية القشرية</u></p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة المعتادة هي ۲٥ ملجم تُعطى مرتين أسبوعيًا أو ٥۰ ملجم مرة واحدة أسبوعيًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بدلًا من ذلك، يمكن إعطاء جرعة قدرها ٥۰ ملجم مرتين أسبوعيًا لمدة تصل إلى ۱۲ أسبوعًا، تتبعها جرعة قدرها ۲٥ ملجم مرتين أسبوعيًا أو ٥۰ ملجم مرة واحدة أسبوعيًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيحدد طبيبك الفترة التي ينبغي عليك تناول إنبريل خلالها وإذا ما كانت تلزم إعادة العلاج بناءً على استجابتك أم لا. إذا لم يكن لإنبريل تأثير على حالتك بعد ۱۲ أسبوعًا، فقد يطلب منك طبيبك أن تتوقف عن تناول هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاستخدام مع الأطفال والمراهقين</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف تعتمد الجرعة ومعدل إعطاء الجرعات الملائمان للطفل أو المراهق على وزن الجسم والمرض. سيحدد طبيبك الجرعة الصحيحة للطفل وسيصف التركيز الملائم من إنبريل (۱۰ ملجم، أو ۲٥ ملجم، أو ٥۰ ملجم).</p><p dir="RTL">&nbsp;</p><p dir="RTL">بالنسبة لالتهاب المفاصل المتعددة أو التهاب المفاصل القليلة الممتد لدى المرضى من سن عامين، أو التهاب المفاصل المتعلق بالتهاب الارتكاز أو التهاب المفاصل الصدفي لدى المرضى من سن ۱۲ عامًا، فإن الجرعة المعتادة هي ۰.٤ ملجم من إنبريل لكل كلجم من وزن الجسم (ما يصل إلى ۲٥ ملجم بحد أقصى) مرتين أسبوعيًا، أو ۰.۸ ملجم من إنبريل لكل كلجم من وزن الجسم (ما يصل إلى ٥۰ ملجم بحد أقصى) مرة واحدة أسبوعيًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أما بالنسبة للصدفية لدى المرضى من سن ٦ أعوام، فإن الجرعة المعتادة هي ۰.۸ ملجم من إنبريل لكل كلجم من وزن الجسم (ما يصل إلى ٥۰ ملجم بحد أقصى)، وينبغي إعطاؤها مرة واحدة أسبوعيًا. إذا لم يكن لإنبريل تأثير على حالة الطفل بعد ۱۲ أسبوعًا، فقد يطلب منك طبيبك أن تتوقف عن استخدام هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقدم لك الطبيب الإرشادات التفصيلية لتحضير وقياس الجرعة الملائمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة ومسار التعاطي</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستعمل إنبريل عن طريق الحقن تحت الجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُمكن تناول إنبريل مع الطعام أو الشراب أو بدونهما.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>توجد تعليمات مفصلة حول كيفية حقن إنبريل في القسم ٧ &quot;تعليمات الاستخدام&quot;. </strong>لا تخلط محلول إنبريل مع أي دواء آخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لمساعدتك على التذكر، قد يكون من المفيد كتابة يوم (أيام) الأسبوع الذي ينبغي فيه استخدام إنبريل في مفكرة يومية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من إنبريل</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا استخدمت كمية أكبر مما ينبغي من إنبريل (إما بحقن كمية أكبر مما ينبغي في المرة الواحدة أو باستخدامه بمعدل أكبر مما ينبغي)، فتحدث إلى طبيب أو صيدلي فورًا. احتفظ معك بعبوة الدواء الكرتونية الخارجية دائمًا، حتى إذا كانت فارغة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة إنبريل</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا نسيت إحدى الجرعات، ينبغي أن تحقنها في أسرع وقت بمجرد أن تتذكرها، ما لم يكن الموعد المحدد للجرعة التالية هو اليوم التالي؛ في تلك الحالة ينبغي أن تتخطى الجرعة الفائتة. بعد ذلك استمر في حقن الدواء في اليوم المعتاد (الأيام المعتادة). إذا لم تتذكر حتى اليوم الذي يحين فيه موعد الحقنة التالية، فلا تتناول جرعة مضاعفة (جرعتين في نفس اليوم) لتعويض الجرعة المنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول إنبريل</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن تعود الأعراض التي تعاني منها عند إيقاف العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، غير أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاعلات الحساسية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا حدث أي مما يلي، فلا تحقن كميات أخرى من إنبريل. أخبر طبيبك فورًا أو اذهب إلى قسم الإصابات في أقرب مستشفى لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود مشكلة في البلع أو التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه، أو الحلق، أو اليدين، أو القدمين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالعصبية أو القلق، الشعور بخفقان، الاحمرار المفاجئ للجلد و/أو الإحساس بالدفء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي الشديد، أو الحكة، أو الشرى (بقع جلدية بارزة حمراء أو باهتة اللون غالبًا ما تثير الحكة)</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن تفاعلات الحساسية الخطيرة نادرة. على الرغم من ذلك، قد تشير أي من الأعراض المذكورة أعلاه إلى وجود تفاعل حساسية تجاه إنبريل، لذلك ينبغي أن تطلب الرعاية الطبية الفورية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الخطيرة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لاحظت أيًا مما يلي، فقد تكون أنت أو الطفل في حاجة إلى رعاية طبية عاجلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات<strong> حالات العدوى الخطيرة</strong>، مثل الحمى المرتفعة التي قد تكون مصحوبة بالسعال، أو ضيق التنفس، أو القشعريرة، أو الضعف، أو وجود منطقة ساخنة حمراء مؤلمة ومتقرحة على الجلد أو المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات <strong>اضطرابات الدم</strong>، مثل النزيف، أو التكدم، أو الشحوب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات <strong>اضطرابات الأعصاب</strong>، مثل الخدر أو التنميل، أو وجود تغيرات في الرؤية، أو ألم في العينين، أو ظهور ضعف في أحد الذراعين أو الساقين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات <strong>فشل القلب</strong> أو <strong>تفاقم فشل القلب</strong>، مثل الإرهاق أو ضيق التنفس عند القيام بنشاط، أو وجود تورم في الكاحلين، أو الإحساس بوجود امتلاء في الرقبة أو البطن، أو ضيق التنفس أو السعال في الليل، أو ازرقاق لون الأظافر أو الشفتين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>علامات السرطانات: </strong>قد تصيب السرطانات أي جزء في الجسم بما في ذلك الجلد والدم، وستعتمد العلامات المحتملة على نوع وموقع السرطان. قد تتضمن هذه العلامات فقدان الوزن، الحمى، التورم (المصحوب أو غير المصحوب بألم)، السعال المستمر، وجود كتل أو أجزاء نامية على الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات <strong>تفاعلات المناعة الذاتية</strong> (حيث تتكون أجسام مضادة قد تضر الأنسجة السليمة في الجسم) مثل الألم، والحكة، والضعف، ووجود اضطراب في التنفس، أو التفكير، أو الشعور، أو الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات الذئبة أو متلازمة شبيهة بالذئبة مثل تغيرات الوزن، أو الطفح الجلدي المستمر، أو الحمى، أو ألم المفاصل أو العضلات، أو الإرهاق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات <strong>التهاب الأوعية الدموية</strong> مثل الألم، أو الحمى، أو احمرار أو دفء الجلد، أو الحكة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذه الآثار جانبية نادرة أو غير شائعة، ولكنها تُعد حالات خطيرة (قد يكون بعضها مميتًا في حالات نادرة). إذا حدثت تلك العلامات، فأخبر طبيبك فورًا، أو قم بزيارة قسم الإصابات في أقرب مستشفى لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتضمن الآثار الجانبية المعروفة لإنبريل الآثار التالية مدرجة في مجموعات مرتبة تنازليًا حسب معدل التكرار:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>شائعة جدًا </strong>(قد تصيب أكثر من شخص واحد من بين كل ۱۰ أشخاص):</p><p dir="RTL">حالات العدوى (بما في ذلك نزلات البرد، والتهاب الجيوب الأنفية، والالتهاب الشعبي، وحالات عدوى الجهاز البولي، وحالات عدوى الجلد)؛ وتفاعلات موضع الحقن (بما في ذلك النزيف، والتكدم، والاحمرار، والحكة، والألم، والتورم) (لا تحدث هذه التفاعلات بنفس المعدل بعد الشهر الأول من العلاج؛ أصيب بعض المرضى بتفاعل عند موضع الحقن الذي سبق استخدامه حديثًا)؛ والصداع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>شائعة </strong>(قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰ أشخاص):</p><p dir="RTL">تفاعلات الحساسية؛ الحمى؛ الطفح الجلدي؛ الحكة؛ توجّه الأجسام المضادة ضد الأنسجة السليمة (تكوين أجسام مضادة ذاتية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>غير شائعة </strong>(قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰۰ شخص):</p><p dir="RTL">حالات العدوى الخطيرة (بما في ذلك الالتهاب الرئوي، وحالات عدوى أنسجة الجلد العميقة، وحالات عدوى المفاصل، وعدوى الدم، وحالات العدوى في مواضع مختلفة)؛ تفاقم حالة فشل القلب الاحتقاني؛ انخفاض تعداد خلايا الدم الحمراء، انخفاض تعداد خلايا الدم البيضاء، انخفاض تعداد العدلات (أحد أنواع خلايا الدم البيضاء)؛ انخفاض تعداد الصفيحات الدموية؛ سرطان الجلد (باستثناء سرطان الخلايا الصبغية)؛ التورم الموضعي في الجلد (التورم الوعائي)؛ الشرى (بقع جلدية بارزة حمراء أو شاحبة اللون غالبًا ما تثير الحكة)؛ التهاب العين؛ الصدفية (إصابة جديدة أو متفاقمة)؛ التهاب الأوعية الدموية الذي يؤثر على أعضاء متعددة؛ ارتفاع قيم نتائج اختبارات الدم لفحص وظائف الكبد (بالنسبة للمرضى الذين يتلقون أيضًا علاجًا بميثوتريكسات، فإن معدل تكرار ارتفاع قيم نتائج اختبارات الدم لفحص وظائف الكبد هو أمر شائع)؛ تقلصات وألم في البطن، أو إسهال، أو فقدان الوزن، أو وجود دم في البراز (علامات لوجود مشكلات بالأمعاء).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>نادرة </strong>(قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰۰۰ شخص):</p><p dir="RTL">تفاعلات الحساسية الخطيرة (بما في ذلك التورم الموضعي الشديد للجلد والأزيز)؛ سرطان الغدد الليمفاوية (أحد أنواع سرطان الدم)؛ ابيضاض الدم (سرطان يصيب الدم ونخاع العظم)؛ سرطان الخلايا الصبغية (أحد أنواع سرطان الجلد)؛ انخفاض تعداد الصفيحات الدموية وخلايا الدم الحمراء والبيضاء بشكل متزامن؛ اضطرابات الجهاز العصبي (مع ضعف عضلي شديد وعلامات وأعراض مشابهة لتلك الخاصة بالتصلب المتعدد أو التهاب أعصاب العينين أو الحبل الشوكي)؛ السل؛ وظهور حالة جديدة من فشل القلب الاحتقاني؛ النوبات؛ الذئبة أو المتلازمة الشبيهة بالذئبة (يمكن أن تتضمن الأعراض الطفح الجلدي المستمر، والحمى، وألم المفاصل، والتعب)؛ الطفح الجلدي الذي قد يؤدي إلى تبثر وتقشر شديدين للجلد؛ التفاعلات الحزازية (طفح جلدي مثير للحكة لونه أرجواني مائل للأحمر و/أو خطوط خيطية الشكل بيضاء ورمادية على الأغشية المخاطية)؛ التهاب الكبد الناتج عن الجهاز المناعي بالجسم نفسه (التهاب الكبد المناعي الذاتي؛ ومعدل التكرار لدى المرضى الذي يتلقون أيضًا العلاج بميثوتريكسات هو غير شائع)؛ الاضطراب المناعي الذي يمكن أن يصيب الرئتين، والجلد، والعقد الليمفاوية (الساركويد)؛ التهاب أو تندّب الرئتين (معدل تكرار التهاب أو تندّب الرئتين غير شائع لدى المرضى الذين يتلقون أيضًا العلاج بميثوتريكسات)؛ تلف في المرشحات الدقيقة الموجودة داخل كليتيك مما يؤدي إلى ضعف وظائف الكليتين (التهاب كبيبات الكلى).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>نادرة جدًا </strong>(قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰۰۰۰ شخص): فشل نخاع العظم في إنتاج خلايا الدم الأساسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>غير معروف </strong>(لا يمكن تقدير معدل التكرار من البيانات المتاحة): سرطانة خلايا ميركل (أحد أنواع سرطان الجلد)؛ ساركوما كابوزي (أحد أنواع السرطان النادرة المرتبطة بالعدوى بفيروس هربس البشري ۸. تظهر ساركوما كابوزي في الأغلب على شكل آفات أرجوانية على الجلد)؛ التنشيط الزائد لخلايا الدم البيضاء المرتبطة بالالتهاب (متلازمة تنشيط البلاعم)؛ معاودة الإصابة بالتهاب الكبد الوبائي B (عدوى بالكبد)؛ تفاقم حالة تُسمى بالتهاب الجلد والعضلات (التهاب وضعف في العضلات يصاحبه طفح جلدي).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية إضافية لدى الأطفال والمراهقين</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية ومعدلات تكرارها التي شوهدت لدى الأطفال والمراهقين مشابهة لتلك الموضحة أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المملكة العربية السعودية</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>المركز الوطني للتيقظ الدوائي (</strong><strong>NPC</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال: ۱۹۹۹۹</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>دول الخليج الأخرى</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>- الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونية وعلى قلم MYCLIC مسبق التعبئة بعد الرمز &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قم بتخزينه في البراد (الثلاجة) (في درجة حرارة من درجتين إلى ۸ درجات مئوية). لا تقم بتجميده.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احتفظ بالأقلام مسبقة التعبئة في العبوة الكرتونية الخارجية لحمايتها من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد إخراج أحد الأقلام مسبقة التعبئة من البراد (الثلاجة)، <strong>انتظر </strong><strong>۱</strong><strong>٥-</strong><strong>۳۰</strong><strong> دقيقة تقريبًا للسماح لمحلول إنبريل الموجود في القلم بالوصول إلى درجة حرارة الغرفة</strong>. لا تقم بتدفئته بأي طريقة أخرى. وعندئذ يوصى بالاستخدام الفوري.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن تخزين إنبريل خارج البراد (الثلاجة) في درجات حرارة تصل إلى ۲٥ درجة مئوية كحد أقصى لفترة واحدة تصل إلى ٤ أسابيع؛ وينبغي عدم تبريد إنبريل مرة أخرى بعد هذه الفترة. ينبغي التخلص من إنبريل إذا لم يتم استخدامه خلال ٤ أسابيع بعد إخراجه من البراد (الثلاجة). يوصى بأن تسجل تاريخ إخراج إنبريل من البراد (الثلاجة) والتاريخ الذي ينبغي التخلص من إنبريل بعده (بعد إخراج الدواء من البراد (الثلاجة) بفترة لا تتعدى ٤ أسابيع).</p><p dir="RTL">&nbsp;</p><p dir="RTL">افحص المحلول الموجود بالقلم من خلال النظر عبر نافذة فحص المحلول الشفافة. ينبغي أن يكون المحلول صافيًا أو براقًا بعض الشيء، أو عديم اللون أو ذا لون أصفر باهت، وقد يحتوي على جسيمات صغيرة بيضاء أو شفافة تقريبًا من البروتين. هذا المظهر طبيعي بالنسبة لإنبريل. لا تستخدم المحلول إذا كان لونه متغيرًا أو إذا كان عكرًا أو كانت هناك جسيمات موجودة بخلاف تلك الموضحة أعلاه. إذا كنت قلقًا بشأن مظهر المحلول، فتواصل مع الصيدلي للمساعدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير في حماية البيئة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة في إنبريل هي إيتانيرسيبت. يحتوي كل قلم MYCLIC مسبق التعبئة على ٥۰ ملجم من إيتانيرسيبت.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكونات الأخرى هي السكروز، وكلوريد الصوديوم، وهيدروكلوريد ل-الأرجنين، وثنائي هيدرات فوسفات الصوديوم أحادي القاعدة، وثنائي هيدرات فوسفات الصوديوم ثنائي القاعدة، وماء للحقن.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يتم توفير إنبريل في صورة محلول مخصص للحقن في قلم مسبق التعبئة (MYCLIC) (محلول للحقن). يحتوي قلم MYCLIC على محلول صافٍ أو عديم اللون أو ذي لون أصفر باهت مخصص للحقن. تحتوي كل عبوة على قلمين أو ٤ أو ۱۲ قلمًا ومسحتين كحوليتين أو ٤ أو ۱۲ مسحة كحولية. قد لا يتم طرح جميع أحجام العبوات في الأسواق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق والمصنع</strong></p><p dir="RTL">&nbsp;</p><p>Pfizer Saudi Limited, Saudi Arabia</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة الصانعه:</strong></p><p dir="RTL">&nbsp;</p><p>Pfizer Manufacturing Belgium NV, Puurs, Belgium</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p><strong>شركة التغليف والفسح النهائي:</strong></p><p>&nbsp;</p><p>Pfizer Saudi Limited, King Abdullah Economic City, Saudi Arabia</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ابريل 2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Enbrel 50 mg solution for injection in pre-filled pen.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Enbrel 50 mg solution for injection in pre-filled pen 
Each pre-filled pen contains 50 mg of etanercept.

Etanercept is a human tumour necrosis factor receptor p75 Fc fusion protein produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian expression system. Etanercept is a dimer of a chimeric protein genetically engineered by fusing the extracellular ligand binding domain of human tumour necrosis factor receptor-2 (TNFR2/p75) to the Fc domain of human IgG1. This Fc component contains the hinge, CH2 and CH3 regions, but not the CH1 region of IgG1. Etanercept contains 934 amino acids and has an apparent molecular weight of approximately 150 kilodaltons. The specific activity of etanercept is 1.7 x 106 units/mg.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection.

The solution is clear, and colourless or pale yellow.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Rheumatoid arthritis</u></p><p>Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate.</p><p>&nbsp;</p><p>Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.</p><p>&nbsp;</p><p>Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.</p><p>&nbsp;</p><p>Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function.</p><p><u>&nbsp;</u></p><p><u>Juvenile idiopathic arthritis</u></p><p>Treatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2&nbsp;years who have had an inadequate response to, or who have proved intolerant of, methotrexate.</p><p>&nbsp;</p><p>Treatment of psoriatic arthritis in adolescents from the age of 12&nbsp;years who have had an inadequate response to, or who have proved intolerant of, methotrexate.</p><p>&nbsp;</p><p>Treatment of enthesitis-related arthritis in adolescents from the age of 12&nbsp;years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Psoriatic arthritis</u></p><p>Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. <em>Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral<strong> </strong>joint damage as measured by X‑ray in patients with polyarticular symmetrical subtypes of the disease.</em></p><p>&nbsp;</p><p><u>Axial spondyloarthritis</u></p><p>&nbsp;</p><p><u>Ankylosing spondylitis (AS)</u></p><p>Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.</p><p>&nbsp;</p><p><u>Non-radiographic axial spondyloarthritis</u></p><p>Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs).</p><p>&nbsp;</p><p><u>Plaque psoriasis</u></p><p>Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA) (see section 5.1).</p><p>&nbsp;</p><p><u>Pediatrics plaque psoriasis</u></p><p>Treatment of chronic severe plaque psoriasis in children and adolescents from the age of 6&nbsp;years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Enbrel treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non‑radiographic axial spondyloarthritis, plaque psoriasis or pediatrics plaque psoriasis. Patients treated with Enbrel should be given the Patient Card.</p><p>&nbsp;</p><p>The Enbrel pre-filled pen is available in a 50&nbsp;mg strength.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p><em>Rheumatoid arthritis</em></p><p>25&nbsp;mg Enbrel administered twice weekly is the recommended dose. Alternatively, 50&nbsp;mg administered once weekly has been shown to be safe and effective (see section 5.1).</p><p>&nbsp;</p><p><em>Psoriatic arthritis, ankylosing spondylitis and non‑radiographic axial spondyloarthritis</em></p><p>The recommended dose is 25&nbsp;mg Enbrel administered twice weekly, or 50&nbsp;mg administered once weekly.</p><p>&nbsp;</p><p>For all of the above indications, available data suggest that a clinical response is usually achieved within 12 weeks of treatment. Continued therapy should be carefully reconsidered in a patient not responding within this time period.</p><p>&nbsp;</p><p><em>Plaque psoriasis</em></p><p>The recommended dose of Enbrel is 25&nbsp;mg administered twice weekly or 50&nbsp;mg administered once weekly. Alternatively, 50&nbsp;mg given twice weekly may be used for up to 12&nbsp;weeks followed, if necessary, by a dose of 25&nbsp;mg twice weekly or 50&nbsp;mg once weekly. Treatment with Enbrel should continue until remission is achieved, for up to 24&nbsp;weeks. Continuous therapy beyond 24&nbsp;weeks may be appropriate for some adult patients (see section 5.1). Treatment should be discontinued in patients who show no response after 12&nbsp;weeks. If re-treatment with Enbrel is indicated, the same guidance on treatment duration should be followed. The dose should be 25&nbsp;mg twice weekly or 50&nbsp;mg once weekly.</p><p><u>&nbsp;</u></p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Renal and hepatic impairment</em></p><p>No dose adjustment is required.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>No dose adjustment is required. Posology and administration are the same as for adults 18-64 years of age.</p><p><em>&nbsp;</em></p><p><em>Pediatrics population</em></p><p>The dosage of Enbrel is based on body weight for pediatrics patients. Patients weighing less than 62.5&nbsp;kg should be accurately dosed on a mg/kg basis using the powder and solvent for solution for injection presentations or the powder for solution for injection presentations (see below for dosing for specific indication). Patients weighing 62.5&nbsp;kg or more, may be dosed using a fixed-dose pre-filled syringe or pre-filled pen.</p><p>&nbsp;</p><p>The safety and efficacy of Enbrel in children aged less than 2 years has not been established.</p><p>No data are available.</p><p>&nbsp;</p><p><em>Juvenile idiopathic arthritis </em></p><p>The recommended dose is 0.4&nbsp;mg/kg (up to a maximum of 25&nbsp;mg per dose), given twice weekly as a subcutaneous injection with an interval of 3-4&nbsp;days between doses or 0.8&nbsp;mg/kg (up to a maximum of 50&nbsp;mg per dose) given once weekly. Discontinuation of treatment should be considered in patients who show no response after 4 months.</p><p>&nbsp;</p><p>The 10&nbsp;mg vial strength may be more appropriate for administration to children with JIA below the weight of 25&nbsp;kg.</p><p>&nbsp;</p><p>No formal clinical trials have been conducted in children aged 2 to 3 years. However, limited safety data from a patient registry suggest that the safety profile in children from 2 to 3 years of age is similar to that seen in adults and children aged 4 years and older, when dosed every week with 0.8&nbsp;mg/kg subcutaneously (see section 5.1).</p><p>&nbsp;</p><p>There is generally no applicable use of Enbrel in children aged below 2 years in the indication juvenile idiopathic arthritis.</p><p>&nbsp;</p><p>Pediatrics plaque psoriasis (age 6 years and above)</p><p>The recommended dose is 0.8&nbsp;mg/kg (up to a maximum of 50&nbsp;mg per dose) once weekly for up to 24&nbsp;weeks. Treatment should be discontinued in patients who show no response after 12 weeks.</p><p>&nbsp;</p><p>If re-treatment with Enbrel is indicated, the above guidance on treatment duration should be followed. The dose should be 0.8&nbsp;mg/kg (up to a maximum of 50&nbsp;mg per dose) once weekly.</p><p>&nbsp;</p><p>There is generally no applicable use of Enbrel in children aged below 6&nbsp;years in the indication plaque psoriasis.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Enbrel is administered by subcutaneous injection (see section 6.6).</p><p>&nbsp;</p><p>Comprehensive instructions for administration are given in the package leaflet, section 7, &ldquo;Instructions for use.&rdquo; Detailed instructions on unintentional dosing or scheduling variations, including missed doses, are provided in section 3 of the package leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Sepsis or risk of sepsis.

Treatment with Enbrel should not be initiated in patients with active infections including chronic or localised infections.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In order to improve the traceability of biological medicinal products, the brand name and batch number of the administered product should be clearly recorded (or stated) in the patient file.</p><p>&nbsp;</p><p><u>Infections</u></p><p>&nbsp;</p><p>Patients should be evaluated for infections before, during, and after treatment with Enbrel, taking into consideration that the mean elimination half-life of etanercept is approximately 70&nbsp;hours (range 7 to 300&nbsp;hours).</p><p>&nbsp;</p><p>Serious infections, sepsis, tuberculosis, and opportunistic infections, including invasive fungal infections, listeriosis and legionellosis, have been reported with the use of Enbrel (see section 4.8). These infections were due to bacteria, mycobacteria, fungi, viruses and parasites (including protozoa). In some cases, particular fungal and other opportunistic infections have not been recognised, resulting in delay of appropriate treatment and sometimes death. In evaluating patients for infections, the patient&rsquo;s risk for relevant opportunistic infections (e.g., exposure to endemic mycoses) should be considered.</p><p>&nbsp;</p><p>Patients who develop a new infection while undergoing treatment with Enbrel should be monitored closely. Administration of Enbrel should be discontinued if a patient develops a serious infection. The safety and efficacy of Enbrel in patients with chronic infections have not been evaluated. Physicians should exercise caution when considering the use of Enbrel in patients with a history of recurring or chronic infections or with underlying conditions that may predispose patients to infections such as advanced or poorly controlled diabetes.</p><p><strong>&nbsp;</strong></p><p><u>Tuberculosis</u></p><p>&nbsp;</p><p>Cases of active tuberculosis including miliary tuberculosis and tuberculosis with extra-pulmonary location have been reported in patients treated with Enbrel.</p><p>&nbsp;</p><p>Before starting treatment with Enbrel, all patients must be evaluated for both active and inactive (&lsquo;latent&rsquo;) tuberculosis. This evaluation should include a detailed medical history with personal history of tuberculosis or possible previous contact with tuberculosis and previous and/or current immunosuppressive therapy. Appropriate screening tests, i.e., tuberculin skin test and chest X-ray, should be performed in all patients (local recommendations may apply). It is recommended that the conduct of these tests should be recorded in the Patient Card. Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in patients who are severely ill or immunocompromised.</p><p>&nbsp;</p><p>If active tuberculosis is diagnosed, Enbrel therapy must not be initiated. If inactive (&lsquo;latent&rsquo;) tuberculosis is diagnosed, treatment for latent tuberculosis must be started with anti-tuberculosis therapy before the initiation of Enbrel, and in accordance with local recommendations. In this situation, the benefit/risk balance of Enbrel therapy should be very carefully considered.</p><p>&nbsp;</p><p>All patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis (e.g., persistent cough, wasting/weight loss, low-grade fever) appear during or after Enbrel treatment.</p><p>&nbsp;</p><p><u>Hepatitis B reactivation</u></p><p>&nbsp;</p><p>Reactivation of hepatitis B in patients who were previously infected with the hepatitis B virus (HBV) and had received concomitant TNF-antagonists, including Enbrel, has been reported. This includes reports of reactivation of hepatitis B in patients who were anti-HBc positive but HBsAg negative. Patients should be tested for HBV infection before initiating treatment with Enbrel. For patients who test positive for HBV infection, consultation with a physician with expertise in the treatment of hepatitis B is recommended. Caution should be exercised when administering Enbrel in patients previously infected with HBV. These patients should be monitored for signs and symptoms of active HBV infection throughout therapy and for several weeks following termination of therapy. Adequate data from treating patients infected with<strong> </strong>HBV with anti-viral therapy in conjunction with TNF‑antagonist therapy are not available. In patients who develop HBV infection, Enbrel should be stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated.</p><p>&nbsp;</p><p><u>Worsening of hepatitis C</u></p><p>&nbsp;</p><p>There have been reports of worsening of hepatitis C in patients receiving Enbrel. Enbrel should be used with caution in patients with a history of hepatitis C.</p><p><strong>&nbsp;</strong></p><p><u>Concurrent treatment with anakinra </u></p><p>&nbsp;</p><p>Concurrent administration of Enbrel and anakinra has been associated with an increased risk of serious infections and neutropenia compared to Enbrel alone. This combination has not demonstrated increased clinical benefit. Thus the combined use of Enbrel and anakinra is not recommended (see sections 4.5 and 4.8).</p><p>&nbsp;</p><p><u>Concurrent treatment with abatacept </u></p><p>&nbsp;</p><p>In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences of serious adverse events. This combination has not demonstrated increased clinical benefit; such use is not recommended (see&nbsp;section 4.5).</p><p>&nbsp;</p><p><u>Allergic reactions</u></p><p>&nbsp;</p><p>Allergic reactions associated with Enbrel administration have been reported commonly. Allergic reactions have included angioedema and urticaria; serious reactions have occurred. If any serious allergic or anaphylactic reaction occurs, Enbrel therapy should be discontinued immediately and appropriate therapy initiated.</p><p>&nbsp;</p><p>The needle cap of the pre-filled pen contains latex (dry natural rubber) that may cause hypersensitivity reactions when handled by or when Enbrel is administered to persons with known or possible latex sensitivity.</p><p>&nbsp;</p><p><u>Immunosuppression</u></p><p>&nbsp;</p><p>The possibility exists for TNF-antagonists, including Enbrel, to affect host defences against infections and malignancies since TNF mediates inflammation and modulates cellular immune responses. In a study of 49 adult patients with rheumatoid arthritis treated with Enbrel, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector cell populations.</p><p>&nbsp;</p><p>Two juvenile idiopathic arthritis patients developed varicella infection and signs and symptoms of aseptic meningitis, which resolved without sequelae. Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with Varicella Zoster Immune Globulin.</p><p>&nbsp;</p><p>The safety and efficacy of Enbrel in patients with immunosuppression have not been evaluated.</p><p>&nbsp;</p><p><u>Malignancies and lymphoproliferative disorders</u></p><p>&nbsp;</p><p><em>Solid and haematopoietic malignancies (excluding skin cancers)</em></p><p>Reports of various malignancies (including breast and lung carcinoma and lymphoma) have been received in the postmarketing period (see section 4.8).</p><p>&nbsp;</p><p>In the controlled portions of clinical trials of TNF-antagonists, more cases of lymphoma have been observed among patients receiving a TNF-antagonist compared with control patients. However, the occurrence was rare, and the follow-up period of placebo patients was shorter than for patients receiving TNF-antagonist therapy. In the postmarketing setting, cases of leukaemia have been reported in patients treated with TNF-antagonists. There is an increased background risk for lymphoma and leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, which complicates risk estimation.</p><p>&nbsp;</p><p>Based on current knowledge, a possible risk for the development of lymphomas, leukaemia or other haematopoietic or solid malignancies in patients treated with a TNF-antagonist cannot be excluded. Caution should be exercised when considering TNF-antagonist therapy for patients with a history of malignancy or when considering continuing treatment in patients who develop a malignancy.</p><p>&nbsp;</p><p>Malignancies, some fatal, have been reported among children, adolescents and young adults (up to 22&nbsp;years of age) treated with TNF-antagonists (initiation of therapy &le; 18 years of age), including Enbrel, in the postmarketing setting. Approximately half the cases were lymphomas. The other cases represented a variety of different malignancies and included rare malignancies typically associated with immunosuppression. A risk for the development of malignancies in children and adolescents treated with TNF-antagonists cannot be excluded.</p><p>&nbsp;</p><p><em>Skin cancers</em></p><p>Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNF‑antagonists, including Enbrel. Postmarketing cases of Merkel cell carcinoma have been reported very infrequently in patients treated with Enbrel. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.</p><p>&nbsp;</p><p>Combining the results of controlled clinical trials, more cases of NMSC were observed in patients receiving Enbrel compared with control patients, particularly in patients with psoriasis.</p><p>&nbsp;</p><p><u>Vaccinations</u></p><p>&nbsp;</p><p>Live vaccines should not be given concurrently with Enbrel. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel. In a double blind, placebo controlled, randomised clinical study in adult patients with psoriatic arthritis 184 patients also received a multivalent pneumococcal polysaccharide vaccine at week 4. In this study most psoriatic arthritis patients receiving Enbrel were able to mount effective B-cell immune response to pneumococcal polysaccharide vaccine, but titres in aggregate were moderately lower and few patients had two-fold rises in titres compared to patients not receiving Enbrel. The clinical significance of this is unknown.</p><p>&nbsp;</p><p><u>Autoantibody formation</u></p><p>&nbsp;</p><p>Treatment with Enbrel may result in the formation of autoimmune antibodies (see section 4.8).</p><p><u>&nbsp;</u></p><p><u>Haematologic reactions</u></p><p>&nbsp;</p><p>Rare cases of pancytopenia and very rare cases of aplastic anaemia, some with fatal outcome, have been reported in patients treated with Enbrel. Caution should be exercised in patients being treated with Enbrel who have a previous history of blood dyscrasias. All patients and parents/caregivers should be advised that if the patient develops signs and symptoms suggestive of blood dyscrasias or infections (e.g., persistent fever, sore throat, bruising, bleeding, paleness) whilst on Enbrel, they should seek immediate medical advice. Such patients should be investigated urgently, including full blood count; if blood dyscrasias are confirmed, Enbrel should be discontinued.</p><p>&nbsp;</p><p><u>Neurological disorders</u></p><p>&nbsp;</p><p>There have been rare reports of CNS demyelinating disorders in patients treated with Enbrel (see section 4.8). Additionally, there have been rare reports of peripheral demyelinating polyneuropathies (including Guillain-Barr&eacute; syndrome, chronic inflammatory demyelinating polyneuropathy, demyelinating polyneuropathy, and multifocal motor neuropathy). Although no clinical trials have been performed evaluating Enbrel therapy in patients with multiple sclerosis, clinical trials of other TNF antagonists in patients with multiple sclerosis have shown increases in disease activity. A careful risk/benefit evaluation, including a neurologic assessment, is recommended when prescribing Enbrel to patients with pre-existing or recent onset of demyelinating disease, or to those who are considered to have an increased risk of developing demyelinating disease.</p><p>&nbsp;</p><p><u>Combination therapy</u></p><p>&nbsp;</p><p>In a controlled clinical trial of two years duration in rheumatoid arthritis patients, the combination of Enbrel and methotrexate did not result in unexpected safety findings, and the safety profile of Enbrel when given in combination with methotrexate was similar to the profiles reported in studies of Enbrel and methotrexate alone. Long-term studies to assess the safety of the combination are ongoing. The long-term safety of Enbrel in combination with other disease-modifying antirheumatic drugs (DMARD) has not been established.</p><p>&nbsp;</p><p>The use of Enbrel in combination with other systemic therapies or phototherapy for the treatment of psoriasis has not been studied.</p><p>&nbsp;</p><p><u>Renal and hepatic impairment</u></p><p>&nbsp;</p><p>Based on pharmacokinetic data (see section 5.2), no dose adjustment is needed in patients with renal or hepatic impairment; clinical experience in such patients is limited.</p><p>&nbsp;</p><p><u>Congestive heart failure</u><u> (</u><u>Cardiac failure congestive)</u></p><p>&nbsp;</p><p>Physicians should use caution when using Enbrel in patients who have congestive heart failure (CHF). There have been postmarketing reports of worsening of CHF, with and without identifiable precipitating factors, in patients taking Enbrel. There have also been rare (&lt;&nbsp;0.1%) reports of new onset CHF, including CHF in patients without known pre‑existing cardiovascular disease. Some of these patients have been under 50&nbsp;years of age. Two large clinical trials evaluating the use of Enbrel in the treatment of CHF were terminated early due to lack of efficacy. Although not conclusive, data from one of these trials suggest a possible tendency toward worsening CHF in those patients assigned to Enbrel treatment.</p><p><u>&nbsp;</u></p><p><u>Alcoholic hepatitis</u></p><p>&nbsp;</p><p>In a phase II randomised placebo-controlled study of 48 hospitalised patients treated with Enbrel or placebo for moderate to severe alcoholic hepatitis, Enbrel was not efficacious, and the mortality rate in patients treated with Enbrel was significantly higher after 6&nbsp;months. Consequently, Enbrel should not be used in patients for the treatment of alcoholic hepatitis. Physicians should use caution when using Enbrel in patients who also have moderate to severe alcoholic hepatitis.</p><p><strong>&nbsp;</strong></p><p><u>Wegener&#39;s granulomatosis</u></p><p>&nbsp;</p><p>A placebo-controlled trial, in which 89 adult patients were treated with Enbrel in addition to standard therapy (including cyclophosphamide or methotrexate, and glucocorticoids) for a median duration of 25&nbsp;months, has not shown Enbrel to be an effective treatment for Wegener&rsquo;s granulomatosis. The incidence of non-cutaneous malignancies of various types was significantly higher in patients treated with Enbrel than in the control group. Enbrel is not recommended for the treatment of Wegener&rsquo;s granulomatosis.</p><p>&nbsp;</p><p><u>Hypoglycaemia in patients treated for diabetes</u></p><p>&nbsp;</p><p>There have been reports of hypoglycaemia following initiation of Enbrel in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly</em></p><p>In the Phase 3 studies in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, no overall differences in adverse events, serious adverse events, and serious infections in patients age 65 or older who received Enbrel were observed compared with younger patients. However, caution should be exercised when treating the elderly and particular attention paid with respect to occurrence of infections.</p><p>&nbsp;</p><p><em>Pediatrics population</em></p><p>&nbsp;</p><p><em><u>Vaccinations</u></em></p><p>It is recommended that pediatrics patients, if possible, be brought up to date with all immunisations in agreement with current immunisation guidelines prior to initiating Enbrel therapy (see Vaccinations, above).</p><p>&nbsp;</p><p><u>Sodium content</u></p><p>&nbsp;</p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dosage unit. Patients on low sodium diets can be informed that this medicinal product is essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Concurrent treatment with anakinra </u></p><p>Adult patients treated with Enbrel and anakinra were observed to have a higher rate of serious infection when compared with patients treated with either Enbrel or anakinra alone (historical data).</p><p>&nbsp;</p><p>In addition, in a double-blind placebo-controlled trial in adult patients receiving background methotrexate, patients treated with Enbrel and anakinra were observed to have a higher rate of serious infections (7%) and neutropenia than patients treated with Enbrel (see sections 4.4 and 4.8). The combination Enbrel and anakinra has not demonstrated increased clinical benefit and is therefore not recommended.</p><p>&nbsp;</p><p><u>Concurrent treatment with abatacept </u></p><p>In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences of serious adverse events. This combination has not demonstrated increased clinical benefit; such use is not recommended (see section 4.4).</p><p>&nbsp;</p><p><u>Concurrent treatment with sulfasalazine </u></p><p>In a clinical study of adult patients who were receiving established doses of sulfasalazine, to which Enbrel was added, patients in the combination group experienced a statistically significant decrease in mean white blood cell counts in comparison to groups treated with Enbrel or sulfasalazine alone. The clinical significance of this interaction is unknown. Physicians should use caution when considering combination therapy with sulfasalazine.</p><p>&nbsp;</p><p><u>Non-interactions</u></p><p>In clinical trials, no interactions have been observed when Enbrel was administered with glucocorticoids, salicylates (except sulfasalazine), nonsteroidal anti-inflammatory drugs (NSAIDs), analgesics, or methotrexate. See section 4.4 for vaccination advice.</p><p>&nbsp;</p><p>No clinically significant pharmacokinetic drug-drug interactions were observed in studies with methotrexate, digoxin or warfarin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>&nbsp;</p><p>Women of childbearing potential should consider the use of appropriate contraception to avoid becoming pregnant during Enbrel therapy and for three weeks after discontinuation of therapy.</p><p><u>&nbsp;</u></p><p><u>Pregnancy </u></p><p>&nbsp;</p><p>Developmental toxicity studies performed in rats and rabbits have revealed no evidence of harm to the foetus or neonatal rat due to etanercept. The effects of etanercept on pregnancy outcomes have been investigated in two observational cohort studies. A higher rate of major birth defects was observed in one observational study comparing pregnancies exposed to etanercept (n=370) during the first trimester with pregnancies not exposed to etanercept or other TNF‑antagonists (n=164) (adjusted odds ratio 2.4, 95% CI: 1.0‑5.5). The types of major birth defects were consistent with those most commonly reported in the general population and no particular pattern of abnormalities was identified. No change in the rate of spontaneous abortion, stillbirth, or minor malformations was observed. In another observational multi‑country registry study comparing the risk of adverse pregnancy outcomes in women exposed to etanercept during the first 90&nbsp;days of pregnancy (n=425) to those exposed to non-biologic drugs (n=3497), there was no observed increased risk of major birth defects (crude odds ratio [OR]= 1.22, 95% CI: 0.79-1.90; adjusted OR = 0.96, 95% CI: 0.58-1.60 after adjusting for country, maternal disease, parity, maternal age and smoking in early pregnancy). This study also showed no increased risks of minor birth defects, preterm birth, stillbirth, or infections in the first year of life for infants born to women exposed to etanercept during pregnancy. Enbrel should only be used during pregnancy if clearly needed.</p><p><u>&nbsp;</u></p><p>Etanercept crosses the placenta and has been detected in the serum of infants born to female patients treated with Enbrel during pregnancy. The clinical impact of this is unknown, however, infants may be at increased risk of infection. Administration of live vaccines to infants for 16&nbsp;weeks after the mother&rsquo;s last dose of Enbrel is generally not recommended.</p><p><u>&nbsp;</u></p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>In lactating rats following subcutaneous administration, etanercept was excreted in the milk and detected in the serum of pups. Limited information from the published literature indicates etanercept has been detected at low levels in human milk. Etanercept could be considered for use during breast‑feeding taking into account the benefit of breast‑feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p>While systemic exposure in a breastfed infant is expected to be low because etanercept is largely degraded in the gastrointestinal tract, limited data regarding systemic exposure in the breastfed infant are available. Therefore, the administration of live vaccines (e.g., BCG) to a breastfed infant when the mother is receiving etanercept could be considered 16 weeks after stopping breast-feeding (or at an earlier timepoint if the infant etanercept serum levels are undetectable).</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Preclinical data about peri- and postnatal toxicity of etanercept and of effects of etanercept on fertility and general reproductive performance are not available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Enbrel has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most commonly reported adverse reactions are injection site reactions (such as pain, swelling, itching, reddening and bleeding at the puncture site), infections (such as upper respiratory infections, bronchitis, bladder infections and skin infections), headache, allergic reactions, development of autoantibodies, itching, and fever.</p><p>&nbsp;</p><p>Serious adverse reactions have also been reported for Enbrel. TNF-antagonists, such as Enbrel, affect the immune system and their use may affect the body&rsquo;s defenses against infection and cancer. Serious infections affect fewer than 1 in 100 patients treated with Enbrel. Reports have included fatal and life‑threatening infections and sepsis. Various malignancies have also been reported with use of Enbrel, including cancers of the breast, lung, skin and lymph glands (lymphoma).&nbsp;</p><p>&nbsp;</p><p>Serious haematological, neurological and autoimmune reactions have also been reported. These include rare reports of pancytopenia and very rare reports of aplastic anaemia. Central and peripheral demyelinating events have been seen rarely and very rarely, respectively, with Enbrel use. There have been rare reports of lupus, lupus-related conditions, and vasculitis.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The following list of adverse reactions is based on experience from clinical trials and on postmarketing experience.</p><p>&nbsp;</p><p>Within the organ system classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare (&lt;&nbsp;1/10,000); not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:106%"><thead><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Very Common</p><p>&ge;&nbsp;1/10</p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Common</p><p>&ge;&nbsp;1/100 to &lt;&nbsp;1/10</p><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Uncommon</p><p>&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p><p>&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very Rare</p><p>&lt;&nbsp;1/10,000</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not Known (Cannot be Estimated from Available Data)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Infection (including upper respiratory tract infection, bronchitis, cystitis, skin infection)*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Serious infections (including pneumonia, cellulitis, arthritis bacterial, sepsis and parasitic infection)*</p></td><td style="vertical-align:top"><p>Tuberculosis, opportunistic infection<em> </em>(including invasive fungal, protozoal, bacterial, atypical mycobacterial, viral infections, and Legionella)*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatitis B reactivation, listeria</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasms benign, malignant and unspecified (including cysts and polyps)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Non-melanoma skin cancers* (see section 4.4)</p></td><td style="vertical-align:top"><p>Malignant melanoma (see section 4.4), lymphoma, leukaemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Merkel cell carcinoma (see section 4.4), Kaposi&rsquo;s sarcoma</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Thrombocytopenia, anaemia, leukopenia, neutropenia</p></td><td style="vertical-align:top"><p>Pancytopenia*</p></td><td style="vertical-align:top"><p>Aplastic anaemia*</p></td><td style="vertical-align:top"><p>Histiocytosis haematophagic (macrophage activation syndrome)*</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Allergic reactions (see Skin and subcutaneous tissue disorders), autoantibody formation*</p></td><td colspan="2" style="vertical-align:top"><p>Vasculitis (including anti-neutrophilic cytoplasmic antibody positive vasculitis)</p></td><td style="vertical-align:top"><p>Serious allergic/anaphylactic reactions (including angioedema, bronchospasm), sarcoidosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Worsening of symptoms of dermatomyositis</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>CNS demyelinating events suggestive of multiple sclerosis or localised demyelinating conditions, such as optic neuritis and transverse myelitis (see section 4.4), peripheral demyelinating events, including Guillain-Barr&eacute; syndrome, chronic inflammatory demyelinating polyneuropathy, demyelinating polyneuropathy, and multifocal motor neuropathy (see section 4.4), seizure</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Uveitis, scleritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Worsening of cardiac failure congestive (see section 4.4)</p></td><td style="vertical-align:top"><p>New onset cardiac failure congestive (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic, and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interstitial lung disease (including pneumonitis and pulmonary fibrosis)*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Inflammatory bowel disease</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Elevated liver enzymes*</p></td><td style="vertical-align:top"><p>Autoimmune hepatitis*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pruritus, rash</p></td><td colspan="2" style="vertical-align:top"><p>Angioedema, psoriasis (including new onset or worsening and pustular, primarily palms and soles), urticaria, psoriasiform rash</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome, cutaneous vasculitis (including hypersensitivity vasculitis), erythema multiforme, lichenoid reactions</p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, lupus-like syndrome</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Glomerulonephritis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Injection site reactions (including bleeding, bruising, erythema, itching, pain, swelling)*</p></td><td style="vertical-align:top"><p>Pyrexia</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>*see Description of selected adverse reactions, below.</p></td><td colspan="4" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Malignancies and lymphoproliferative disorders</em></p><p>One hundred and twenty-nine new malignancies of various types were observed in 4,114 rheumatoid arthritis patients treated in clinical trials with Enbrel for up to approximately 6&nbsp;years, including 231&nbsp;patients treated with Enbrel in combination with methotrexate in the 2‑year active‑controlled study. The observed rates and incidences in these clinical trials were similar to those expected for the population studied. A total of 2 malignancies were reported in clinical studies of approximately 2 years duration involving 240 Enbrel-treated psoriatic arthritis patients. In clinical studies conducted for more than 2&nbsp;years with 351 ankylosing spondylitis patients, 6&nbsp;malignancies were reported in Enbrel-treated patients. In a group of 2,711 plaque psoriasis patients treated with Enbrel in double‑blind and open-label studies of up to 2.5 years, 30 malignancies and 43 nonmelanoma skin cancers were reported.</p><p>&nbsp;</p><p>In a group of 7,416&nbsp;patients treated with Enbrel in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and psoriasis clinical trials, 18 lymphomas were reported.</p><p>&nbsp;</p><p>Reports of various malignancies (including breast and lung carcinoma and lymphoma) have also been received in the postmarketing period (see section 4.4).</p><p><strong>&nbsp;</strong></p><p><em>Injection site reactions</em></p><p>Compared to placebo, patients with rheumatic diseases treated with Enbrel had a significantly higher incidence of injection site reactions (36% vs. 9%). Injection site reactions usually occurred in the first month. Mean duration was approximately 3 to 5 days. No treatment was given for the majority of injection site reactions in the Enbrel treatment groups, and the majority of patients who were given treatment received topical preparations such as corticosteroids, or oral antihistamines. Additionally, some patients developed recall injection site reactions characterised by a skin reaction at the most recent site of injection along with the simultaneous appearance of injection site reactions at previous injection sites. These reactions were generally transient and did not recur with treatment.</p><p>&nbsp;</p><p>In controlled trials in patients with plaque psoriasis, approximately 13.6% of patients treated with Enbrel developed injection site reactions compared with 3.4% of placebo-treated patients during the first 12 weeks of treatment.</p><p>&nbsp;</p><p><em>Serious infections</em></p><p>In placebo-controlled trials, no increase in the incidence of serious infections (fatal, life threatening, or requiring hospitalisation or intravenous antibiotics) was observed. Serious infections occurred in 6.3% of rheumatoid arthritis patients treated with Enbrel for up to 48&nbsp;months. These included abscess (at various sites), bacteraemia, bronchitis, bursitis, cellulitis, cholecystitis, diarrhoea, diverticulitis, endocarditis (suspected), gastroenteritis, hepatitis B, herpes zoster, leg ulcer, mouth infection, osteomyelitis, otitis, peritonitis, pneumonia, pyelonephritis, sepsis, septic arthritis, sinusitis, skin infection, skin ulcer, urinary tract infection, vasculitis, and wound infection. In the 2-year active‑controlled study where patients were treated with either Enbrel alone, methotrexate alone or Enbrel in combination with methotrexate, the rates of serious infections were similar among the treatment groups. However, it cannot be excluded that the combination of Enbrel with methotrexate could be associated with an increase in the rate of infections.</p><p>&nbsp;</p><p>There were no differences in rates of infection among patients treated with Enbrel and those treated with placebo for plaque psoriasis in placebo‑controlled trials of up to 24 weeks duration. Serious infections experienced by Enbrel-treated patients included cellulitis, gastroenteritis, pneumonia, cholecystitis, osteomyelitis, gastritis, appendicitis, Streptococcal fasciitis, myositis, septic shock, diverticulitis and abscess. In the double-blind and open-label psoriatic arthritis trials, 1&nbsp;patient reported a serious infection (pneumonia).</p><p>&nbsp;</p><p>Serious and fatal infections have been reported during use of Enbrel; reported pathogens include bacteria, mycobacteria (including tuberculosis), viruses and fungi. Some have occurred within a few weeks after initiating treatment with Enbrel in patients who have underlying conditions (e.g., diabetes, congestive heart failure, history of active or chronic infections) in addition to their rheumatoid arthritis (see section&nbsp;4.4). Enbrel treatment may increase mortality in patients with established sepsis.</p><p>&nbsp;</p><p>Opportunistic infections have been reported in association with Enbrel, including invasive fungal, parasitic (including protozoal), viral (including herpes zoster), bacterial (including <em>Listeria</em> and <em>Legionella</em>), and atypical mycobacterial infections. In a pooled data set of clinical trials, the overall incidence of opportunistic infections was 0.09% for the 15,402 subjects who received Enbrel. The exposure‑adjusted rate was 0.06&nbsp;events per 100&nbsp;patient‑years. In postmarketing experience, approximately half of all of the case reports of opportunistic infections worldwide were invasive fungal infections. The most commonly reported invasive fungal infections included<em> Candida,</em> <em>Pneumocystis,</em> <em>Aspergillus, </em>and<em> Histoplasma</em>. Invasive fungal infections accounted for more than half of the fatalities amongst patients who developed opportunistic infections. The majority of the reports with a fatal outcome were in patients with <em>Pneumocystis</em> pneumonia, unspecified systemic fungal infections, and aspergillosis (see section 4.4).</p><p>&nbsp;</p><p><em>Autoantibodies</em></p><p>Adult patients had serum samples tested for autoantibodies at multiple timepoints. Of the rheumatoid arthritis patients evaluated for antinuclear antibodies (ANA), the percentage of patients who developed new positive ANA (&sup3;&nbsp;1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated patients (5%). The percentage of patients who developed new positive anti-double-stranded DNA antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4% of placebo-treated patients) and by <em>Crithidia luciliae</em> assay (3% of patients treated with Enbrel compared to none of placebo-treated patients). The proportion of patients treated with Enbrel who developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients. The impact of long‑term treatment with Enbrel on the development of autoimmune diseases is unknown.</p><p>&nbsp;</p><p>There have been rare reports of patients, including rheumatoid factor positive patients, who have developed other autoantibodies in conjunction with a lupus-like syndrome or rashes that are compatible with subacute cutaneous lupus or discoid lupus by clinical presentation and biopsy.</p><p><strong><u>&nbsp;</u></strong></p><p><em>Pancytopenia and aplastic anaemia</em></p><p>There have been postmarketing reports of pancytopenia and aplastic anaemia, some of which had fatal outcomes (see section 4.4).</p><p>&nbsp;</p><p><em>Interstitial lung disease</em></p><p>In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of interstitial lung disease in patients receiving etanercept without concomitant methotrexate was 0.06% (frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept and methotrexate, the frequency (incidence proportion) of interstitial lung disease was 0.47% (frequency uncommon). There have been postmarketing reports of interstitial lung disease (including pneumonitis and pulmonary fibrosis), some of which had fatal outcomes.</p><p><strong>&nbsp;</strong></p><p><em>Concurrent treatment with anakinra </em></p><p>In studies when adult patients received concurrent treatment with Enbrel plus anakinra, a higher rate of serious infections compared to Enbrel alone was observed and 2% of patients (3/139) developed neutropenia (absolute neutrophil count &lt;&nbsp;1000/mm<sup>3</sup>). While neutropenic, one patient developed cellulitis that resolved after hospitalisation (see sections 4.4 and 4.5).</p><p>&nbsp;</p><p><em>Elevated liver enzymes</em></p><p>In the double-blind periods of controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of adverse events of elevated liver enzymes in patients receiving etanercept without concomitant methotrexate was 0.54% (frequency uncommon). In the double-blind periods of controlled clinical trials that allowed concomitant treatment with etanercept and methotrexate, the frequency (incidence proportion) of adverse events of elevated liver enzymes was 4.18% (frequency common).</p><p>&nbsp;</p><p><em>Autoimmune hepatitis</em></p><p>In controlled clinical trials of etanercept across all indications, the frequency (incidence proportion) of autoimmune hepatitis in patients receiving etanercept without concomitant methotrexate was 0.02% (frequency rare). In the controlled clinical trials that allowed concomitant treatment with etanercept and methotrexate, the frequency (incidence proportion) of autoimmune hepatitis was 0.24% (frequency uncommon).</p><p>&nbsp;</p><p>Pediatrics population</p><p><em>&nbsp;</em></p><p><em>Undesirable effects in </em><em>pediatrics</em><em> patients with juvenile idiopathic arthritis</em></p><p>In general, the adverse events in pediatrics patients with juvenile idiopathic arthritis were similar in frequency and type to those seen in adult patients. Differences from adults and other special considerations are discussed in the following paragraphs.</p><p>&nbsp;</p><p>The types of infections seen in clinical trials in juvenile idiopathic arthritis patients aged 2 to 18&nbsp;years were generally mild to moderate and consistent with those commonly seen in outpatient pediatrics populations. Severe adverse events reported included varicella with signs and symptoms of aseptic meningitis, which resolved without sequelae (see also section 4.4), appendicitis, gastroenteritis, depression/personality disorder, cutaneous ulcer, oesophagitis/gastritis, group A streptococcal septic shock, type I diabetes mellitus, and soft tissue and post-operative wound infection.</p><p>&nbsp;</p><p>In one study in children with juvenile idiopathic arthritis aged 4 to 17&nbsp;years, 43 of 69 (62%) children experienced an infection while receiving Enbrel during 3 months of the study (part 1, open-label), and the frequency and severity of infections was similar in 58 patients completing 12&nbsp;months of open-label extension therapy. The types and proportion of adverse events in juvenile idiopathic arthritis patients were similar to those seen in trials of Enbrel in adult patients with rheumatoid arthritis, and the majority were mild. Several adverse events were reported more commonly in 69 juvenile idiopathic arthritis patients receiving 3 months of Enbrel compared to the 349 adult rheumatoid arthritis patients. These included headache (19% of patients, 1.7 events per patient year), nausea (9%, 1.0 event per patient year), abdominal pain (19%, 0.74 events per patient year), and vomiting (13%, 0.74 events per patient year).</p><p>&nbsp;</p><p>There were 4 reports of macrophage activation syndrome in juvenile idiopathic arthritis clinical trials.</p><p>&nbsp;</p><p><em>Undesirable effects in </em><em>pediatrics</em><em> patients with plaque psoriasis</em></p><p>In a 48-week study in 211 children aged 4 to 17&nbsp;years with pediatrics plaque psoriasis, the adverse events reported were similar to those seen in previous studies in adults with plaque psoriasis.</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to National Pharmacovigilance Centre (NPC).</p><p>&nbsp;</p><p><strong>To report side effects</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp; Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other</strong><strong> GCC States</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No dose-limiting toxicities were observed during clinical trials of rheumatoid arthritis patients. The highest dose level evaluated has been an intravenous loading dose of 32&nbsp;mg/m<sup>2</sup> followed by subcutaneous doses of 16&nbsp;mg/m<sup>2</sup> administered twice weekly. One rheumatoid arthritis patient mistakenly self-administered 62&nbsp;mg Enbrel subcutaneously twice weekly for 3 weeks without experiencing undesirable effects. There is no known antidote to Enbrel.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressants, <em>Tumour Necrosis Factor alpha (TNF-&alpha;) inhibitors</em>, ATC code: L04AB01</p><p>&nbsp;</p><p>Tumour necrosis factor (TNF) is a dominant cytokine in the inflammatory process of rheumatoid arthritis. Elevated levels of TNF are also found in the synovium and psoriatic plaques of patients with psoriatic arthritis and in serum and synovial tissue of patients with ankylosing spondylitis. In plaque psoriasis, infiltration by inflammatory cells including T-cells leads to increased TNF levels in psoriatic lesions compared with levels in uninvolved skin. Etanercept is a competitive inhibitor of TNF-binding to its cell surface receptors and thereby inhibits the biological activity of TNF. TNF and lymphotoxin are pro‑inflammatory cytokines that bind to two distinct cell surface receptors: the 55-kilodalton (p55) and 75‑kilodalton (p75) tumour necrosis factor receptors (TNFRs). Both TNFRs exist naturally in membrane-bound and soluble forms. Soluble TNFRs are thought to regulate TNF biological activity.</p><p>&nbsp;</p><p>TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on cross-linking of cell surface TNFRs. Dimeric soluble receptors such as etanercept possess a higher affinity for TNF than monomeric receptors and are considerably more potent competitive inhibitors of TNF binding to its cellular receptors. In addition, use of an immunoglobulin Fc region as a fusion element in the construction of a dimeric receptor imparts a longer serum half-life.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Much of the joint pathology in rheumatoid arthritis and ankylosing spondylitis and skin pathology in plaque psoriasis is mediated by pro-inflammatory molecules that are linked in a network controlled by TNF. The mechanism of action of etanercept is thought to be its competitive inhibition of TNF binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering TNF biologically inactive. Etanercept may also modulate biologic responses controlled by additional downstream molecules (e.g., cytokines, adhesion molecules, or proteinases) that are induced or regulated by TNF.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>This section presents data from four randomised controlled trials in adults with rheumatoid arthritis, one study in adults with psoriatic arthritis, one study in adults with ankylosing spondylitis, two studies in adults with non‑radiographic axial spondyloarthritis, four studies in adults with plaque psoriasis, three studies in juvenile idiopathic arthritis and one study in pediatrics patients with plaque psoriasis.</p><p>&nbsp;</p><p><em>Adult patients with rheumatoid arthritis</em></p><p>The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study. The study evaluated 234 adult patients with active rheumatoid arthritis who had failed therapy with at least one but no more than four disease-modifying antirheumatic drugs (DMARDs). Doses of 10&nbsp;mg or 25&nbsp;mg Enbrel or placebo were administered subcutaneously twice a week for 6&nbsp;consecutive months. The results of this controlled trial were expressed in percentage improvement in rheumatoid arthritis using American College of Rheumatology (ACR) response criteria.</p><p>&nbsp;</p><p>ACR 20 and 50 responses were higher in patients treated with Enbrel at 3 and 6&nbsp;months than in patients treated with placebo (ACR 20: Enbrel 62% and 59%, placebo 23% and 11% at 3 and 6&nbsp;months respectively: ACR 50: Enbrel 41% and 40%, placebo 8% and 5% at months 3 and 6, respectively; p&nbsp;&lt;&nbsp;0.01 Enbrel vs placebo at all timepoints for both ACR 20 and ACR 50 responses).</p><p>&nbsp;</p><p>Approximately 15% of subjects who received Enbrel achieved an ACR 70 response at month&nbsp;3 and month&nbsp;6&nbsp;compared to fewer than 5% of subjects in the placebo arm. Among patients receiving Enbrel, the clinical responses generally appeared within 1 to 2 weeks after initiation of therapy and nearly always occurred by 3 months. A dose response was seen; results with 10&nbsp;mg were intermediate between placebo and 25&nbsp;mg. Enbrel was significantly better than placebo in all components of the ACR criteria as well as other measures of rheumatoid arthritis disease activity not included in the ACR response criteria, such as morning stiffness. A Health Assessment Questionnaire (HAQ), which included disability, vitality, mental health, general health status, and arthritis-associated health status subdomains, was administered every 3&nbsp;months during the trial. All subdomains of the HAQ were improved in patients treated with Enbrel compared to controls at 3 and 6&nbsp;months.</p><p>&nbsp;</p><p>After discontinuation of Enbrel, symptoms of arthritis generally returned within a month. Re‑introduction of treatment with Enbrel after discontinuation of up to 24 months resulted in the same magnitudes of responses as patients who received Enbrel without interruption of therapy based on results of open‑label studies. Continued durable responses have been seen for up to 10&nbsp;years in open‑label extension treatment trials when patients received Enbrel without interruption.</p><p>&nbsp;</p><p>The efficacy of Enbrel was compared to methotrexate in a randomised, active-controlled study with blinded radiographic evaluations as a primary endpoint in 632 adult patients with active rheumatoid arthritis (&lt;3 years duration) who had never received treatment with methotrexate. Doses of 10&nbsp;mg or 25&nbsp;mg Enbrel were administered SC twice a week for up to 24 months. Methotrexate doses were escalated from 7.5&nbsp;mg/week to a maximum of 20&nbsp;mg/week over the first 8&nbsp;weeks of the trial and continued for up to 24&nbsp;months. Clinical improvement including onset of action within 2&nbsp;weeks with Enbrel 25&nbsp;mg was similar to that seen in the previous trials, and was maintained for up to 24&nbsp;months. At baseline, patients had a moderate degree of disability, with mean HAQ scores of 1.4 to 1.5. Treatment with Enbrel 25&nbsp;mg resulted in substantial improvement at 12&nbsp;months, with about 44% of patients achieving a normal HAQ score (less than 0.5). This benefit was maintained in Year&nbsp;2 of this study.</p><p>&nbsp;</p><p>In this study, structural joint damage was assessed radiographically and expressed as change in Total Sharp Score (TSS) and its components, the erosion score and Joint Space Narrowing (JSN) score. Radiographs of hands/wrists and feet were read at baseline and 6, 12, and 24&nbsp;months. The 10&nbsp;mg Enbrel dose had consistently less effect on structural damage than the 25&nbsp;mg dose. Enbrel 25&nbsp;mg was significantly superior to methotrexate for erosion scores at both 12 and 24 months. The differences in TSS and JSN were not statistically significant between methotrexate and Enbrel 25&nbsp;mg. The results are shown in the figure below.</p><p>&nbsp;</p><p><strong>Radiographic Progression: Comparison of Enbrel vs Methotrexate in Patients with RA of &lt;3&nbsp;Years Duration</strong></p><p><!--[if gte mso 9]><xml>
 <o:OLEObject Type="Embed" ProgID="PowerPoint.Show.8" ShapeID="_x0000_i1025"
  DrawAspect="Content" ObjectID="_1803892507">
 </o:OLEObject>
</xml><![endif]--></p><p>&nbsp;</p><p>In another active-controlled, double-blind, randomised study, clinical efficacy, safety, and radiographic progression in RA patients treated with Enbrel alone (25&nbsp;mg twice weekly), methotrexate alone (7.5 to 20&nbsp;mg weekly, median dose 20&nbsp;mg), and of the combination of Enbrel and methotrexate initiated concurrently were compared in 682 adult patients with active rheumatoid arthritis of 6&nbsp;months to 20&nbsp;years duration (median 5&nbsp;years) who had a less than satisfactory response to at least 1 disease‑modifying antirheumatic drug (DMARD) other than methotrexate.</p><p>&nbsp;</p><p>Patients in the Enbrel in combination with methotrexate therapy group had significantly higher ACR&nbsp;20, ACR 50, ACR 70 responses and improvement for DAS and HAQ scores at both 24 and 52&nbsp;weeks than patients in either of the single therapy groups (results shown in table below). Significant advantages for Enbrel in combination with methotrexate compared with Enbrel monotherapy and methotrexate monotherapy were also observed after 24&nbsp;months.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><thead><tr><td colspan="5" style="vertical-align:top"><p><strong>Clinical Efficacy Results at 12&nbsp;Months: Comparison of Enbrel vs Methotrexate vs Enbrel in Combination with</strong><strong> </strong><strong>Methotrexate in Patients with RA of 6&nbsp;Months To 20&nbsp;Years Duration</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:bottom"><p><strong>Endpoint</strong></p><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>Methotrexate<br />(n = 228)</p></td><td style="vertical-align:bottom"><p>Enbrel<br />(n = 223)</p></td><td style="vertical-align:bottom"><p>Enbrel +<br />Methotrexate<br />(n = 231)</p></td><td><p>&nbsp;</p></td></tr></thead><tbody><tr><td colspan="2" style="vertical-align:top"><p><br /><strong>ACR Responses<sup>a</sup> </strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>ACR 20</p></td><td><p>58.8%</p></td><td><p>65.5%</p></td><td><p>74.5% <strong><sup>&dagger;,</sup></strong><sup>f</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>ACR 50</p></td><td><p>36.4%</p></td><td><p>43.0%</p></td><td><p>63.2% <strong><sup>&dagger;,</sup></strong><sup>f</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>ACR 70</p></td><td><p>16.7%</p></td><td><p>22.0%</p></td><td><p>39.8% <strong><sup>&dagger;,</sup></strong><sup>f</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>DAS</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Baseline score<sup>b</sup></p></td><td style="vertical-align:top"><p>5.5</p></td><td style="vertical-align:top"><p>5.7</p></td><td style="vertical-align:top"><p>5.5</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Week 52 score<sup>b</sup></p></td><td style="vertical-align:top"><p>3.0</p></td><td style="vertical-align:top"><p>3.0</p></td><td style="vertical-align:top"><p>2.3<strong><sup>&dagger;,</sup></strong><sup>f</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Remission<sup>c</sup></p></td><td style="vertical-align:top"><p>14%</p></td><td style="vertical-align:top"><p>18%</p></td><td style="vertical-align:top"><p>37%<strong><sup>&dagger;,</sup></strong><sup>f</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>HAQ</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Baseline</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>1.8</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Week 52</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>0.8<strong><sup>&dagger;,</sup></strong><sup>f</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="5" style="vertical-align:top"><p>a: Patients who did not complete 12 months in the study were considered to be non-responders.</p><p>b: Values for Disease Activity Score (DAS) are means.</p><p>c: Remission is defined as DAS &lt;1.6</p><p>Pairwise comparison p-values: &dagger;<strong> </strong>= p &lt; 0.05 for comparisons of Enbrel + methotrexate vs methotrexate and f<strong> </strong>= p &lt; 0.05 for comparisons of Enbrel + methotrexate vs Enbrel</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>Radiographic progression at 12&nbsp;months was significantly less in the Enbrel group than in the methotrexate group, while the combination was significantly better than either monotherapy at slowing radiographic progression (see figure below).</p><p>&nbsp;</p><p><strong>Radiographic Progression: Comparison of Enbrel vs Methotrexate vs Enbrel in Combination with Methotrexate in Patients with RA of 6&nbsp;Months To 20&nbsp;Years Duration (12&nbsp;Month Results)</strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Pairwise comparison p-values: * = p &lt; 0.05 for comparisons of Enbrel vs methotrexate, &dagger; = p &lt; 0.05 for comparisons of Enbrel + methotrexate vs methotrexate and f = p&nbsp;&lt;&nbsp;0.05 for comparisons of Enbrel + methotrexate vs Enbrel</p><p>&nbsp;</p><p>Significant advantages for Enbrel in combination with methotrexate compared with Enbrel monotherapy and methotrexate monotherapy were also observed after 24&nbsp;months. Similarly, the significant advantages for Enbrel monotherapy compared with methotrexate monotherapy were also observed after 24&nbsp;months.</p><p><strong>&nbsp;</strong></p><p>In an analysis in which all patients who dropped out of the study for any reason were considered to have progressed, the percentage of patients without progression (TSS change &le;&nbsp;0.5) at 24&nbsp;months was higher in the Enbrel in combination with methotrexate group compared with the Enbrel alone and methotrexate alone groups&nbsp;(62%, 50%, and 36%, respectively; p&lt;&nbsp;0.05). The difference between Enbrel alone and methotrexate alone was also significant (p&lt;&nbsp;0.05). Among patients who completed a full 24&nbsp;months of therapy in the study, the non-progression rates were 78%, 70%, and 61%, respectively.</p><p>&nbsp;</p><p>The safety and efficacy of 50&nbsp;mg Enbrel (two 25&nbsp;mg SC injections) administered once weekly were evaluated in a double-blind, placebo-controlled study of 420 patients with active RA. In this study, 53 patients received placebo, 214 patients received 50&nbsp;mg Enbrel once weekly and 153 patients received 25&nbsp;mg Enbrel twice weekly. The safety and efficacy profiles of the two Enbrel treatment regimens were comparable at week 8 in their effect on signs and symptoms of RA; data at week 16&nbsp;did not show comparability (non-inferiority) between the two regimens. A single 50&nbsp;mg/ml injection of Enbrel was found to be bioequivalent to two simultaneous injections of 25&nbsp;mg/ml.</p><p>&nbsp;</p><p><em>Adult patients with psoriatic arthritis</em></p><p>The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 205 patients with psoriatic arthritis. Patients were between 18 and 70&nbsp;years of age and had active psoriatic arthritis (&sup3;&nbsp;3 swollen joints and &sup3;&nbsp;3 tender joints) in at least one of the following forms: (1)&nbsp;distal interphalangeal (DIP) involvement; (2)&nbsp;polyarticular arthritis (absence of rheumatoid nodules and presence of psoriasis); (3)&nbsp;arthritis mutilans; (4)&nbsp;asymmetric psoriatic arthritis; or (5)&nbsp;spondylitis-like ankylosis. Patients also had plaque psoriasis with a qualifying target lesion &sup3;&nbsp;2&nbsp;cm in diameter. Patients had previously been treated with NSAIDs (86%), DMARDs (80%), and corticosteroids (24%). Patients currently on methotrexate therapy (stable for &sup3; 2 months) could continue at a stable dose of &pound;&nbsp;25&nbsp;mg/week methotrexate. Doses of 25&nbsp;mg of Enbrel (based on dose-finding studies in patients with rheumatoid arthritis) or placebo were administered SC twice a week for 6&nbsp;months. At the end of the double-blind study, patients could enter a long-term open-label extension study for a total duration of up to 2&nbsp;years.</p><p>&nbsp;</p><p>Clinical responses were expressed as percentages of patients achieving the ACR 20, 50, and 70 response and percentages with improvement in Psoriatic Arthritis Response Criteria (PsARC). Results are summarised in the table below.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><thead><tr><td colspan="3" style="vertical-align:top">&nbsp;<p><strong>Responses of Patients with Psoriatic Arthritis in a Placebo‑Controlled Trial</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Percent of Patients</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Enbrel<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; Psoriatic Arthritis Response</p></td><td style="vertical-align:top"><p>n = 104</p></td><td style="vertical-align:top"><p>n = 101</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp; </strong><strong>ACR 20</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Month 3</p></td><td style="vertical-align:top"><p>15</p></td><td style="vertical-align:top"><p>59<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Month 6</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>50<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp; ACR 50</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Month 3</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>38<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Month 6</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>37<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp; ACR 70</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Month 3</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>11<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Month 6</p></td><td style="vertical-align:top"><p>1</p></td><td style="vertical-align:top"><p>9<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong><u>&nbsp;</u></strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp; PsARC</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Month 3</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>72<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Month 6</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>70<sup>b</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>a: 25&nbsp;mg Enbrel SC twice weekly</p><p>b: p &lt; 0.001, Enbrel vs. placebo</p><p>c: p &lt; 0.01, Enbrel vs. placebo</p></td></tr></tbody></table><p>&nbsp;</p><p>Among patients with psoriatic arthritis who received Enbrel, the clinical responses were apparent at the time of the first visit (4&nbsp;weeks) and were maintained through 6&nbsp;months of therapy. Enbrel was significantly better than placebo in all measures of disease activity (p&nbsp;&lt;&nbsp;0.001), and responses were similar with and without concomitant methotrexate therapy. Quality of life in psoriatic arthritis patients was assessed at every timepoint using the disability index of the HAQ. The disability index score was significantly improved at all timepoints in psoriatic arthritis patients treated with Enbrel, relative to placebo (p&nbsp;&lt;&nbsp;0.001).</p><p>&nbsp;</p><p>Radiographic changes were assessed in the psoriatic arthritis study. Radiographs of hands and wrists were obtained at baseline and months 6, 12, and 24. The modified TSS at 12 months is presented in the Table below. In an analysis in which all patients who dropped out of the study for any reason were considered to have progressed, the percentage of patients without progression (TSS change &le; 0.5) at 12&nbsp;months was higher in the Enbrel group compared with the placebo group (73% vs. 47%, respectively, p&nbsp;&le;&nbsp;0.001). The effect of Enbrel on radiographic progression was maintained in patients who continued on treatment during the second year. The slowing of peripheral joint damage was observed in patients with polyarticular symmetrical joint involvement.&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:638px"><tbody><tr><td colspan="3" style="vertical-align:top"><p>Mean (SE) Annualized Change from Baseline in Total Sharp Score</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>Etanercept</p></td></tr><tr><td style="vertical-align:top"><p>Time</p></td><td style="vertical-align:top"><p>(n = 104)</p></td><td style="vertical-align:top"><p>(n = 101)</p></td></tr><tr><td style="vertical-align:top"><p>Month 12</p></td><td style="vertical-align:top"><p>1.00 (0.29)</p></td><td style="vertical-align:top"><p>‑0.03 (0.09)<sup>a</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>SE = standard error.&nbsp;</p><p>a. p = 0.0001.&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Enbrel treatment resulted in improvement in physical function during the double‑blind period, and this benefit was maintained during the longer‑term exposure of up to 2&nbsp;years.</p><p>&nbsp;</p><p>There is insufficient evidence of the efficacy of Enbrel in patients with ankylosing spondylitis‑like and arthritis mutilans<strong> </strong>psoriatic arthropathies due to the small number of patients studied.</p><p>No study has been performed in patients with psoriatic arthritis using the 50&nbsp;mg once weekly dosing regimen. Evidence of efficacy for the once weekly dosing regimen in this patient population has been based on data from the study in patients with ankylosing spondylitis.</p><p>&nbsp;</p><p><em>Adult patients with ankylosing spondylitis</em></p><p>The efficacy of Enbrel in ankylosing spondylitis was assessed in 3 randomised, double-blind studies comparing twice weekly administration of 25&nbsp;mg Enbrel with placebo. A total of 401 patients were enrolled from which 203 were treated with Enbrel. The largest of these trials (n= 277) enrolled patients who were between 18 and 70&nbsp;years of age and had active ankylosing spondylitis defined as visual analog scale (VAS) scores of &sup3;&nbsp;30 for average of duration and intensity of morning stiffness plus VAS scores of &sup3;&nbsp;30 for at least 2 of the following 3 parameters: patient global assessment; average of VAS values for nocturnal back pain and total back pain; average of 10 questions on the Bath Ankylosing Spondylitis Functional Index (BASFI). Patients receiving DMARDs, NSAIDS, or corticosteroids could continue them on stable doses. Patients with complete ankylosis of the spine were not included in the study. Doses of 25&nbsp;mg of Enbrel (based on dose-finding studies in patients with rheumatoid arthritis) or placebo were administered subcutaneously twice a week for 6&nbsp;months in 138&nbsp;patients.</p><p>&nbsp;</p><p>The primary measure of efficacy (ASAS 20) was a &sup3;&nbsp;20% improvement in at least 3 of the 4 Assessment in Ankylosing Spondylitis (ASAS) domains (patient global assessments, back pain, BASFI, and inflammation) and absence of deterioration in the remaining domain. ASAS 50 and 70 responses used the same criteria with a 50% improvement or a 70% improvement, respectively.</p><p>&nbsp;</p><p>Compared to placebo, treatment with Enbrel resulted in significant improvements in the ASAS 20, ASAS 50 and ASAS 70 as early as 2 weeks after the initiation of therapy.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Responses of Patients with Ankylosing Spondylitis in a Placebo-Controlled Trial</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Percent of Patients</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp; Ankylosing Spondylitis Response</p></td><td style="vertical-align:top"><p>Placebo</p><p>N = 139</p></td><td style="vertical-align:top"><p>Enbrel</p><p>N = 138</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; ASAS 20</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 2 weeks</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>46<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 3 months</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>60<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 6&nbsp;months</p></td><td style="vertical-align:top"><p>23</p></td><td style="vertical-align:top"><p>58<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; ASAS 50</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 2 weeks</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>24<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 3 months</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>45<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 6&nbsp;months</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>42<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp; ASAS 70:</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 2 weeks</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>12<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 3 months</p></td><td style="vertical-align:top"><p>7</p></td><td style="vertical-align:top"><p>29<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp; 6&nbsp;months</p></td><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>28<sup>b</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&nbsp;a: p &lt;0.001, Enbrel vs. Placebo</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>&nbsp;b: p = 0.002, Enbrel vs. placebo</p></td></tr></tbody></table><p>&nbsp;</p><p>Among patients with ankylosing spondylitis who received Enbrel, the clinical responses were apparent at the time of the first visit (2&nbsp;weeks) and were maintained through 6&nbsp;months of therapy. Responses were similar in patients who were or were not receiving concomitant therapies at baseline.</p><p>&nbsp;</p><p>Similar results were obtained in the 2 smaller ankylosing spondylitis trials.</p><p>&nbsp;</p><p>In a fourth study, the safety and efficacy of 50&nbsp;mg Enbrel (two 25&nbsp;mg SC injections) administered once weekly vs 25&nbsp;mg Enbrel administered twice weekly were evaluated in a double-blind, placebo‑controlled study of 356&nbsp;patients with active ankylosing spondylitis. The safety and efficacy profiles of the 50&nbsp;mg once weekly and 25&nbsp;mg twice weekly regimens were similar.</p><p>&nbsp;</p><p><em>Adult patients with non-radiographic axial spondyloarthritis</em></p><p><u>&nbsp;</u></p><p><em><u>Study 1</u></em></p><p>The efficacy of Enbrel in patients with non‑radiographic axial spondyloarthritis (nr-AxSpa) was assessed in a randomised, 12-week double-blind, placebo-controlled study. The study evaluated 215&nbsp;adult patients (modified intent-to-treat population) with active nr-AxSpa (18 to 49&nbsp;years of age), defined as those patients meeting the ASAS classification criteria of axial spondyloarthritis but did not meet the modified New York criteria for AS. Patients were also required to have an inadequate response or intolerance to two or more NSAIDs. In the double-blind period, patients received Enbrel 50&nbsp;mg weekly or placebo for 12 weeks. The primary measure of efficacy (ASAS 40) was a 40% improvement in at least three of the four ASAS domains and absence of deterioration in the remaining domain. The double-blind period was followed by an open‑label period during which all patients receive Enbrel 50&nbsp;mg weekly for up to an additional 92 weeks. MRIs of the sacroiliac joint and spine were obtained to assess inflammation at baseline and at weeks&nbsp;12 and 104.</p><p>&nbsp;</p><p>Compared to placebo, treatment with Enbrel resulted in statistically significant improvement in the ASAS 40, ASAS 20 and ASAS 5/6. Significant improvement was also observed for the ASAS partial remission and BASDAI 50. Week 12 results are shown in the table below.</p><p>&nbsp;</p><p><strong>Efficacy Response in Placebo-Controlled nr-AxSpa Study: Percent of Patients Achieving Endpoints</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Double-Blind Clinical</p><p>Responses at Week 12</p></td><td style="vertical-align:top"><p>Placebo</p><p>N=106 to 109*</p></td><td style="vertical-align:top"><p>Enbrel</p><p>N=103 to 105*</p></td></tr><tr><td style="vertical-align:top"><p>ASAS** 40</p></td><td style="vertical-align:top"><p>15.7</p></td><td style="vertical-align:top"><p>32.4<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>ASAS 20</p></td><td style="vertical-align:top"><p>36.1</p></td><td style="vertical-align:top"><p>52.4<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>ASAS 5/6</p></td><td style="vertical-align:top"><p>10.4</p></td><td style="vertical-align:top"><p>33.0<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>ASAS partial remission</p></td><td style="vertical-align:top"><p>11.9</p></td><td style="vertical-align:top"><p>24.8<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>BASDAI***50</p></td><td style="vertical-align:top"><p>23.9</p></td><td style="vertical-align:top"><p>43.8<sup>b</sup></p></td></tr></tbody></table><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>*Some patients did not provide complete data for each endpoint</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>**ASAS=Assessments in Spondyloarthritis International Society</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ***Bath Ankylosing Spondylitis Disease Activity Index</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a: p &lt;0.001, b:&lt;0.01 and c:&lt;0.05, respectively between Enbrel and placebo</p><p>&nbsp;</p><p>At week&nbsp;12, there was a statistically significant improvement in the SPARCC (Spondyloarthritis Research Consortium of Canada) score for the sacroiliac joint (SIJ) as measured by MRI for patients receiving Enbrel. Adjusted mean change from baseline was 3.8 for Enbrel treated (n=95) versus 0.8 for placebo treated (n=105) patients (p&lt;0.001). At week&nbsp;104, the mean change from baseline in the SPARCC score measured on MRI for all Enbrel-treated subjects was 4.64 for the SIJ (n=153) and 1.40&nbsp;the spine (n=154).</p><p>&nbsp;</p><p>Enbrel showed statistically significantly greater improvement from baseline to week 12 compared to placebo in most health‑related quality of life and physical function assessments, including BASFI (Bath Ankylosing Spondylitis Functional Index), EuroQol 5D Overall Health State Score and SF-36 Physical Component Score.</p><p>&nbsp;</p><p>Clinical responses among nr-AxSpa patients who received Enbrel were apparent at the time of the first visit (2&nbsp;weeks) and were maintained through 2&nbsp;years of therapy. Improvements in health‑related quality of life and physical function were also maintained through 2&nbsp;years of therapy. The 2&nbsp;year data did not reveal any new safety findings. At week&nbsp;104, 8&nbsp;subjects had progressed to a score of bilateral Grade&nbsp;2 on spinal X-ray according to the modified New York Radiological Grade, indicative of axial spondyloarthropathy.</p><p>&nbsp;</p><p><em><u>Study 2</u></em></p><p>This multi-center, open-label, phase 4, 3-period study evaluated the withdrawal and retreatment of Enbrel in patients with active nr-AxSpa who achieved an adequate response (inactive disease defined as Ankylosing Spondylitis Disease Activity Score (ASDAS) C-reactive protein (CRP) less than 1.3) following 24&nbsp;weeks of treatment.</p><p>&nbsp;</p><p>209&nbsp;adult patients with active nr-AxSpa (18 to 49&nbsp;years of age), defined as those patients meeting the Assessment of SpondyloArthritis International Society (ASAS) classification criteria of axial spondyloarthritis (but not meeting the modified New York criteria for AS), having positive MRI findings (active inflammation on MRI highly suggestive of sacroiliitis associated with SpA) and/or positive hsCRP (defined as high sensitivity C-reactive protein [hsCRP] &gt;&nbsp;3&nbsp;mg/l), and active symptoms defined by an ASDAS CRP greater than or equal to 2.1 at the screening visit received open‑label Enbrel 50&nbsp;mg weekly plus stable background NSAID at the optimal tolerated anti‑inflammatory dosage for 24&nbsp;weeks in Period 1. Patients were also required to have an inadequate response or intolerance to two or more NSAIDs. At week&nbsp;24, 119 (57%) patients achieved inactive disease and entered into the Period 2 40-week withdrawal phase where subjects discontinued etanercept, yet maintained the background NSAID. The primary measure of efficacy was the occurrence of flare (defined as an ASDAS erythrocyte sedimentation rate (ESR) greater than or equal to 2.1) within 40&nbsp;weeks following withdrawal of Enbrel. Patients who flared were retreated with Enbrel 50&nbsp;mg weekly for 12&nbsp;weeks (Period 3).</p><p>&nbsp;</p><p>In Period&nbsp;2, the proportion of patients experiencing &ge;1 flare increased from 22% (25/112) at week 4 to 67% (77/115) at week 40. Overall, 75% (86/115) patients experienced a flare at any time point within 40&nbsp;weeks following withdrawal of Enbrel.</p><p>&nbsp;</p><p>The key secondary objective of Study 2 was to estimate time to flare after withdrawal of Enbrel and additionally compare the time to flare to patients from Study 1 who met the Study&nbsp;2 withdrawal phase entry requirements and continued Enbrel therapy. &nbsp;</p><p>&nbsp;</p><p>The median time to flare following withdrawal of Enbrel was 16 weeks (95% CI: 13-24&nbsp;weeks).&nbsp;Less than 25% of patients in Study&nbsp;1 who did not have treatment withdrawn experienced a flare over the equivalent 40-weeks as in Period 2 Study 2. The time to flare was statistically significantly shorter in subjects who discontinued Enbrel treatment (Study 2) compared to subjects who received continuous etanercept treatment (Study 1), p&lt;0.0001.</p><p>&nbsp;</p><p>Of the 87&nbsp;patients who entered Period 3 and were retreated with Enbrel 50&nbsp;mg weekly for 12&nbsp;weeks, 62% (54/87) reachieved inactive disease, with 50% of them reachieving it within 5&nbsp;weeks (95% CI: 4‑8&nbsp;weeks).</p><p><em>&nbsp;</em></p><p><em>Adult patients with plaque psoriasis</em></p><p>Enbrel is recommended for use in patients as defined in section 4.1. Patients who &ldquo;failed to respond to&rdquo; in the target population is defined by insufficient response (PASI&lt;&nbsp;50 or PGA less than good), or worsening of the disease while on treatment, and who were adequately dosed for a sufficiently long duration to assess response with at least one of the three major systemic therapies as available.</p><p>&nbsp;</p><p>The efficacy of Enbrel versus other systemic therapies in patients with moderate to severe psoriasis (responsive to other systemic therapies) has not been evaluated in studies directly comparing Enbrel with other systemic therapies. Instead, the safety and efficacy of Enbrel were assessed in four randomised, double-blind, placebo-controlled studies. The primary efficacy endpoint in all four studies was the proportion of patients in each treatment group who achieved the PASI 75 (i.e., at least a 75% improvement in the Psoriasis Area and Severity Index score from baseline) at 12&nbsp;weeks.</p><p>&nbsp;</p><p>Study 1 was a Phase 2 study in patients with active but clinically stable plaque psoriasis involving &sup3;&nbsp;10% of the body surface area that were &sup3;&nbsp;18 years old. One hundred and twelve (112) patients were randomised to receive a dose of 25&nbsp;mg of Enbrel (n=57) or placebo (n=55) twice a week for 24&nbsp;weeks.</p><p>&nbsp;</p><p>Study 2 evaluated 652 patients with chronic plaque psoriasis using the same inclusion criteria as study 1 with the addition of a minimum psoriasis area and severity index (PASI) of 10 at screening. Enbrel was administered at doses of 25&nbsp;mg once a week, 25&nbsp;mg twice a week or 50&nbsp;mg twice a week for 6&nbsp;consecutive months. During the first 12 weeks of the double-blind treatment period, patients received placebo or one of the above three Enbrel doses. After 12&nbsp;weeks of treatment, patients in the placebo group began treatment with blinded Enbrel (25&nbsp;mg twice a week); patients in the active treatment groups continued to week&nbsp;24 on the dose to which they were originally randomised.</p><p>&nbsp;</p><p>Study&nbsp;3 evaluated 583 patients and had the same inclusion criteria as study&nbsp;2. Patients in this study received a dose of 25&nbsp;mg or 50&nbsp;mg Enbrel, or placebo twice a week for 12&nbsp;weeks and then all patients received open-label 25&nbsp;mg Enbrel twice weekly for an additional 24&nbsp;weeks.</p><p>&nbsp;</p><p>Study&nbsp;4 evaluated 142 patients and had similar inclusion criteria to studies&nbsp;2 and 3. Patients in this study received a dose of 50&nbsp;mg Enbrel or placebo once weekly for 12&nbsp;weeks and then all patients received open-label 50&nbsp;mg Enbrel once weekly for an additional 12&nbsp;weeks.</p><p>&nbsp;</p><p>In study 1, the Enbrel-treated group had a significantly higher proportion of patients with a PASI 75 response at week 12 (30%) compared to the placebo-treated group (2%) (p&lt;&nbsp;0.0001). At 24 weeks, 56% of patients in the Enbrel-treated group had achieved the PASI 75 compared to 5% of placebo‑treated patients. Key results of studies 2, 3 and 4 are shown below.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:631px"><tbody><tr><td colspan="12" style="vertical-align:top"><p><strong>Responses of Patients with Psoriasis in Studies 2, 3 And 4</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:bottom"><p>Response (%)</p></td><td colspan="5" style="vertical-align:top"><p>------------------Study 2---------------</p></td><td colspan="3" style="vertical-align:top"><p>---------------Study 3-------------</p></td><td colspan="3" style="vertical-align:top"><p>---------------Study 4-------------</p></td></tr><tr><td rowspan="2" style="vertical-align:bottom"><p>Placebo</p></td><td colspan="4" style="vertical-align:top"><p>----------Enbrel---------</p></td><td rowspan="2" style="vertical-align:bottom"><p>Placebo</p></td><td colspan="2" style="vertical-align:top"><p>--------Enbrel-------</p></td><td rowspan="2" style="vertical-align:bottom"><p>Placebo</p></td><td colspan="2" style="vertical-align:top"><p>-------Enbrel------</p></td></tr><tr><td colspan="2" style="vertical-align:bottom"><p>25&nbsp;mg</p><p>BIW</p></td><td colspan="2" style="vertical-align:bottom"><p>50&nbsp;mg</p><p>BIW</p></td><td style="vertical-align:bottom"><p>25&nbsp;mg</p><p>BIW</p></td><td style="vertical-align:bottom"><p>50&nbsp;mg</p><p>BIW</p></td><td style="vertical-align:bottom"><p>50&nbsp;mg QW</p></td><td style="vertical-align:bottom"><p>50&nbsp;mg</p><p>QW</p></td></tr><tr><td style="vertical-align:top"><p>n = 166</p><p>wk 12</p></td><td style="vertical-align:top"><p>n = 162</p><p>wk 12</p></td><td style="vertical-align:top"><p>n = 162</p><p>wk 24<sup>a</sup></p></td><td style="vertical-align:top"><p>n = 164</p><p>wk 12</p></td><td style="vertical-align:top"><p>n = 164</p><p>wk 24<sup>a</sup></p></td><td style="vertical-align:top"><p>n = 193</p><p>wk 12</p></td><td style="vertical-align:top"><p>n = 196</p><p>wk 12</p></td><td style="vertical-align:top"><p>n = 196</p><p>wk 12</p></td><td style="vertical-align:top"><p>n = 46</p><p>wk 12</p></td><td style="vertical-align:top"><p>n = 96</p><p>wk 12</p></td><td style="vertical-align:top"><p>n = 90</p><p>wk 24<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>PASI 50</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>58*</p></td><td style="vertical-align:top"><p>70</p></td><td style="vertical-align:top"><p>74*</p></td><td style="vertical-align:top"><p>77</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>64*</p></td><td style="vertical-align:top"><p>77*</p></td><td style="vertical-align:top"><p>9</p></td><td style="vertical-align:top"><p>69*</p></td><td style="vertical-align:top"><p>83</p></td></tr><tr><td style="vertical-align:top"><p>PASI 75</p></td><td style="vertical-align:top"><p>4</p></td><td style="vertical-align:top"><p>34*</p></td><td style="vertical-align:top"><p>44</p></td><td style="vertical-align:top"><p>49*</p></td><td style="vertical-align:top"><p>59</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>34*</p></td><td style="vertical-align:top"><p>49*</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>38*</p></td><td style="vertical-align:top"><p>71</p></td></tr><tr><td style="vertical-align:bottom"><p>DSGA<sup> b</sup>, clear or almost clear</p></td><td style="vertical-align:bottom"><p>5</p></td><td style="vertical-align:bottom"><p>34*</p></td><td style="vertical-align:bottom"><p>39</p></td><td style="vertical-align:bottom"><p>49*</p></td><td style="vertical-align:bottom"><p>55</p></td><td style="vertical-align:bottom"><p>4</p></td><td style="vertical-align:bottom"><p>39*</p></td><td style="vertical-align:bottom"><p>57*</p></td><td style="vertical-align:bottom"><p>4</p></td><td style="vertical-align:bottom"><p>39*</p></td><td style="vertical-align:bottom"><p>64</p></td></tr><tr><td colspan="12" style="vertical-align:top"><p>*p &pound; 0.0001 compared with placebo</p><p>a. No statistical comparisons to placebo were made at week 24 in studies 2 and 4 because the original placebo group began receiving Enbrel 25&nbsp;mg BIW or 50&nbsp;mg once weekly from week 13 to week 24.</p><p>b. Dermatologist Static Global Assessment. Clear or almost clear defined as 0 or 1 on a 0 to 5 scale.</p></td></tr></tbody></table><p>&nbsp;</p><p>Among patients with plaque psoriasis who received Enbrel, significant responses relative to placebo were apparent at the time of the first visit (2 weeks) and were maintained through 24 weeks of therapy.</p><p>&nbsp;</p><p>Study 2 also had a drug withdrawal period during which patients who achieved a PASI improvement of at least 50% at week 24 had treatment stopped. Patients were observed off treatment for the occurrence of rebound (PASI &sup3;&nbsp;150% of baseline) and for the time to relapse (defined as a loss of at least half of the improvement achieved between baseline and week 24). During the withdrawal period, symptoms of psoriasis gradually returned with a median time to disease relapse of 3 months. No rebound flare of disease and no psoriasis-related serious adverse events were observed. There was some evidence to support a benefit of re-treatment with Enbrel in patients initially responding to treatment.</p><p>&nbsp;</p><p>In study 3, the majority of patients (77%) who were initially randomised to 50&nbsp;mg twice weekly and had their Enbrel dose decreased at week 12 to 25&nbsp;mg twice weekly maintained their PASI 75 response through week 36. For patients who received 25&nbsp;mg twice weekly throughout the study, the PASI 75 response continued to improve between weeks 12 and 36.</p><p>&nbsp;</p><p>In study 4, the Enbrel-treated group had a higher proportion of patients with PASI 75 at week 12 (38%) compared to the placebo-treated group (2%) (p&lt;0.0001). For patients who received 50&nbsp;mg once weekly throughout the study, the efficacy responses continued to improve with 71% achieving PASI 75 at week 24.</p><p>&nbsp;</p><p>In long-term (up to 34&nbsp;months) open-label studies where Enbrel was given without interruption, clinical responses were sustained and safety was comparable to shorter-term studies.</p><p>&nbsp;</p><p>An analysis of clinical trial data&nbsp;did not reveal any&nbsp;baseline disease characteristics that would assist clinicians in selecting the most appropriate dosing option (intermittent or continuous). Consequently, the choice of intermittent or continuous therapy should be based upon physician judgment and individual patient needs.</p><p>&nbsp;</p><p><em>Antibodies to Enbrel</em></p><p>Antibodies to etanercept have been detected in the sera of some subjects treated with etanercept. These antibodies have all been non-neutralising and are generally transient. There appears to be no correlation between antibody development and clinical response or adverse events.</p><p>&nbsp;</p><p>In subjects treated with approved doses of etanercept in clinical trials for up to 12&nbsp;months, cumulative rates of anti-etanercept antibodies were approximately 6% of subjects with rheumatoid arthritis, 7.5% of subjects with psoriatic arthritis, 2% of subjects with ankylosing spondylitis, 7% of subjects with psoriasis, 9.7% of subjects with pediatrics psoriasis, and 4.8% of subjects with juvenile idiopathic arthritis.</p><p>&nbsp;</p><p>The proportion of subjects who developed antibodies to etanercept in longer-term trials (of up to 3.5&nbsp;years) increases over time, as expected. However, due to their transient nature, the incidence of antibodies detected at each assessment point was typically less than 7% in rheumatoid arthritis subjects and psoriasis subjects.</p><p>&nbsp;</p><p>In a long-term psoriasis study in which patients received 50&nbsp;mg twice weekly for 96&nbsp;weeks, the incidence of antibodies observed at each assessment point was up to approximately 9%.</p><p>&nbsp;</p><p>Pediatrics population</p><p><em>&nbsp;</em></p><p><em>Pediatrics</em><em> patients with juvenile idiopathic arthritis</em></p><p>The safety and efficacy of Enbrel were assessed in a two-part study in 69 children with polyarticular‑course juvenile idiopathic arthritis who had a variety of juvenile idiopathic arthritis onset types (polyarthritis, pauciarthritis, systemic onset). Patients aged 4 to 17 years with moderately to severely active polyarticular-course juvenile idiopathic arthritis refractory to, or intolerant of, methotrexate were enrolled; patients remained on a stable dose of a single nonsteroidal anti‑inflammatory drug and/or prednisone (&lt;&nbsp;0.2&nbsp;mg/kg/day or 10&nbsp;mg maximum). In part 1, all patients received 0.4&nbsp;mg/kg (maximum 25&nbsp;mg per dose) Enbrel subcutaneously twice weekly. In part 2, patients with a clinical response at day 90 were randomised to remain on Enbrel or receive placebo for four months and assessed for disease flare. Responses were measured using the ACR Pedi 30, defined as &sup3;&nbsp;30% improvement in at least three of six and &sup3;&nbsp;30% worsening in no more than one of six JRA core set criteria, including active joint count, limitation of motion, physician and patient/parent global assessments, functional assessment, and erythrocyte sedimentation rate (ESR). Disease flare was defined as a &sup3;&nbsp;30% worsening in three of six JRA core set criteria and &sup3;&nbsp;30% improvement in not more than one of the six JRA core set criteria and a minimum of two active joints.</p><p>&nbsp;</p><p>In part 1 of the study, 51 of 69 (74%) patients demonstrated a clinical response and entered part 2. In part 2, 6&nbsp;of 25 (24%) patients remaining on Enbrel experienced a disease flare compared to 20 of 26&nbsp;(77%) patients receiving placebo (p=0.007). From the start of part 2, the median time to flare was &sup3;&nbsp;116&nbsp;days for patients who received Enbrel and 28 days for patients who received placebo. Of patients who demonstrated a clinical response at 90 days and entered part 2 of the study, some of the patients remaining on Enbrel continued to improve from month 3 through month 7, while those who received placebo did not improve.</p><p>&nbsp;</p><p>In an open-label, safety extension study, 58 paediatric patients from the above study (from the age of 4&nbsp;years at time of enrolment) continued to receive Enbrel for up to 10&nbsp;years. Rates of serious adverse events and serious infections did not increase with long-term exposure.</p><p>&nbsp;</p><p>Long-term safety of Enbrel monotherapy (n=103), Enbrel plus methotrexate (n=294), or methotrexate monotherapy (n=197) were assessed for up to 3 years in a registry of 594 children aged 2 to 18&nbsp;years with juvenile idiopathic arthritis, 39 of whom were 2 to 3 years of age. Overall, infections were more commonly reported in patients treated with etanercept compared to methotrexate alone (3.8 versus 2%), and the infections associated with etanercept use were of a more severe nature.</p><p>&nbsp;</p><p>In another open-label single-arm study (n=127), 60 patients with extended oligoarthritis (EO) (15&nbsp;patients aged 2 to 4, 23 patients aged 5 to 11 and 22 patients aged 12 to 17&nbsp;years old), 38 patients with enthesitis-related arthritis (12 to 17&nbsp;years old), and 29 patients with psoriatic arthritis (12 to 17&nbsp;years old) were treated with Enbrel at a dose of 0.8&nbsp;mg/kg (up to a maximum of 50&nbsp;mg per dose) administered weekly for 12&nbsp;weeks. In each of the JIA subtypes, the majority of patients met ACR Pedi 30 criteria and demonstrated clinical improvement in secondary endpoints such as number of tender joints and physician global assessment. The safety profile was consistent with that observed in other JIA studies.</p><p>&nbsp;</p><p>Of the 127&nbsp;patients in the parent study, 109 participated in the open-label extension study and were followed for an additional 8 years for a total of up to 10 years. At the end of the extension study, 84/109 (77%) patients had completed the study; 27 (25%) while actively taking Enbrel, 7 (6%) had withdrawn from treatment due to low/inactive disease; 5 (5%) had re-started Enbrel following an earlier withdrawal from treatment; and 45 (41%) had stopped Enbrel (but remained under observation); 25/109 (23%) patients permanently discontinued from the study. Improvements in clinical status achieved in the parent study were generally maintained for all efficacy endpoints during the entire follow-up period. Patients actively taking Enbrel could enter an optional withdrawal-retreatment period once during the extension study based on investigator&rsquo;s judgement of clinical response. 30&nbsp;patients entered the withdrawal period. 17&nbsp;patients were reported to have a flare (defined as &ge;&nbsp;30% worsening in at least 3 of the 6 ACR Pedi components with &ge;&nbsp;30% improvement in not more than 1 of the remaining 6 components and a minimum of 2 active joints); median time to flare after Enbrel withdrawal was 190&nbsp;days. 13&nbsp;patients were re-treated and the median time to re-treatment from withdrawal was estimated as 274&nbsp;days. Due to the small number of data points, these results should be interpreted with caution.</p><p>&nbsp;</p><p>The safety profile was consistent with that observed in the parent study.</p><p>&nbsp;</p><p>Studies have not been done in patients with juvenile idiopathic arthritis to assess the effects of continued Enbrel therapy in patients who do not respond within 3 months of initiating Enbrel therapy. Additionally, studies have not been conducted to assess the effects of reducing the recommended dose of Enbrel following its long-term use in patients with JIA.</p><p>&nbsp;</p><p><em>Pediatrics</em><em> patients with plaque psoriasis</em></p><p>The efficacy of Enbrel was assessed in a randomised, double-blind, placebo-controlled study in 211 pediatrics patients aged 4 to 17 years with moderate to severe plaque psoriasis (as defined by a sPGA score &ge;&nbsp;3, involving &ge;&nbsp;10% of the BSA, and PASI &ge;&nbsp;12). Eligible patients had a history of receiving phototherapy or systemic therapy, or were inadequately controlled on topical therapy.</p><p>&nbsp;</p><p>Patients received Enbrel 0.8&nbsp;mg/kg (up to 50&nbsp;mg) or placebo once weekly for 12 weeks. At week 12, more patients randomised to Enbrel had positive efficacy responses (e.g. PASI 75) than those randomised to placebo.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p>&nbsp;Pediatrics Plaque Psoriasis Outcomes at 12 Weeks</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Enbrel</strong></p><p><strong>0.8&nbsp;mg/kg Once Weekly</strong></p><p><strong>(N = 106)</strong></p></td><td style="vertical-align:bottom"><p><strong>Placebo</strong></p><p><strong>(N = 105)</strong></p></td></tr><tr><td style="vertical-align:top"><p>PASI 75, n (%)</p></td><td style="vertical-align:top"><p>60 (57%)<sup>a</sup></p></td><td style="vertical-align:top"><p>12 (11%)</p></td></tr><tr><td style="vertical-align:top"><p>PASI 50, n (%)</p></td><td style="vertical-align:top"><p>79 (75%)<sup>a</sup></p></td><td style="vertical-align:top"><p>24 (23%)</p></td></tr><tr><td style="vertical-align:top"><p>sPGA &ldquo;clear&rdquo; or &ldquo;minimal&rdquo;, n (%)</p></td><td style="vertical-align:top"><p>56&nbsp;(53%)<sup>a</sup></p></td><td style="vertical-align:top"><p>14 (13%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Abbreviation: sPGA-static Physician Global Assessment.</p><p>a.&nbsp;&nbsp; p &lt; 0.0001 compared with placebo.</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>After the 12-week double-blind treatment period, all patients received Enbrel 0.8&nbsp;mg/kg (up to 50&nbsp;mg) once weekly for additional 24 weeks. Responses observed during the open-label period were similar to those observed in the double-blind period.</p><p>&nbsp;</p><p>During a randomised withdrawal period, significantly more patients re-randomised to placebo experienced disease relapse (loss of PASI 75 response) compared with patients re-randomised to Enbrel. With continued therapy, responses were maintained up to 48 weeks.<strong> </strong></p><p><u>&nbsp;</u></p><p>The long-term safety and effectiveness of Enbrel 0.8&nbsp;mg/kg (up to 50&nbsp;mg) once weekly was assessed in an open-label extension study of 181 pediatrics subjects with plaque psoriasis for up to 2 years beyond the 48 week study discussed above. Long-term experience with Enbrel was generally comparable to the original 48-week study and did not reveal any new safety findings.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Etanercept serum values were determined by an Enzyme-Linked Immunosorbent Assay (ELISA) method, which may detect ELISA-reactive degradation products as well as the parent compound.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>&nbsp;</p><p>Etanercept is slowly absorbed from the site of subcutaneous injection, reaching maximum concentration approximately 48&nbsp;hours after a single dose. The absolute bioavailability is 76%. With twice weekly doses, it is anticipated that steady-state concentrations are approximately twice as high as those observed after single doses. After a single subcutaneous dose of 25&nbsp;mg Enbrel, the average maximum serum concentration observed in healthy volunteers was 1.65 &plusmn; 0.66&nbsp;mg/ml, and the area under the curve was 235&nbsp;&plusmn; 96.6&nbsp;mg&middot;hr/ml.</p><p>&nbsp;</p><p>Mean serum concentration profiles at steady state in treated RA patients were C<sub>max</sub> of 2.4&nbsp;mg/l vs. 2.6&nbsp;mg/l, C<sub>min</sub> of 1.2&nbsp;mg/l vs. 1.4&nbsp;mg/l, and partial AUC of 297&nbsp;mgh/l vs. 316&nbsp;mgh/l for 50&nbsp;mg Enbrel once weekly (n=21) vs. 25&nbsp;mg Enbrel twice weekly (n=16), respectively. In an open-label, single-dose, two‑treatment, crossover study in healthy volunteers, etanercept administered as a single 50&nbsp;mg/ml injection was found to be bioequivalent to two simultaneous injections of 25&nbsp;mg/ml.</p><p>&nbsp;</p><p>In a population pharmacokinetics analysis in ankylosing spondylitis patients, the etanercept steady state AUCs were 466&nbsp;mg&middot;hr/ml and 474&nbsp;mg&middot;hr/ml for 50&nbsp;mg Enbrel once weekly (N = 154) and 25&nbsp;mg twice weekly (N = 148), respectively.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>A biexponential curve is required to describe the concentration time curve of etanercept. The central volume of distribution of etanercept is 7.6&nbsp;l, while the volume of distribution at steady-state is 10.4&nbsp;l.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Etanercept is cleared slowly from the body. The half-life is long, approximately 70&nbsp;hours. Clearance is approximately 0.066&nbsp;l/hr in patients with rheumatoid arthritis, somewhat lower than the value of 0.11&nbsp;l/hr observed in healthy volunteers. Additionally, the pharmacokinetics of Enbrel in rheumatoid arthritis patients, ankylosing spondylitis and plaque psoriasis patients are similar.</p><p>&nbsp;</p><p>There is no apparent pharmacokinetic difference between males and females.</p><p><u>&nbsp;</u></p><p><u>Linearity</u></p><p>&nbsp;</p><p>Dose proportionality has not been formally evaluated, but there is no apparent saturation of clearance across the dosing range.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Although there is elimination of radioactivity in urine after administration of radiolabelled etanercept to patients and volunteers, increased etanercept concentrations were not observed in patients with acute renal failure. The presence of renal impairment should not require a change in dosage.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Increased etanercept concentrations were not observed in patients with acute hepatic failure. The presence of hepatic impairment should not require a change in dosage.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>The impact of advanced age was studied in the population pharmacokinetic analysis of etanercept serum concentrations. Clearance and volume estimates in patients aged 65 to 87 years were similar to estimates in patients less than 65 years of age.</p><p>&nbsp;</p><p><u>Pediatrics</u><u> population</u></p><p><em>&nbsp;</em></p><p><em>Pediatrics</em><em> patients with juvenile idiopathic arthritis</em></p><p>In a polyarticular-course juvenile idiopathic arthritis trial with Enbrel, 69 patients (aged&nbsp;4 to 17&nbsp;years) were administered 0.4&nbsp;mg Enbrel/kg twice weekly for three months. Serum concentration profiles were similar to those seen in adult rheumatoid arthritis patients. The youngest children (4&nbsp;years of age) had reduced clearance (increased clearance when normalised by weight) compared with older children (12 years of age) and adults. Simulation of dosing suggests that while older children (10-17&nbsp;years of age) will have serum levels close to those seen in adults, younger children will have appreciably lower levels.</p><p>&nbsp;</p><p><em>Pediatrics</em><em> patients with plaque psoriasis</em></p><p>Patients with pediatrics plaque psoriasis (aged 4 to 17&nbsp;years) were administered 0.8&nbsp;mg/kg (up to a maximum dose of 50&nbsp;mg per week) of etanercept once weekly for up to 48 weeks. The mean serum steady state trough concentrations ranged from 1.6&nbsp;to 2.1&nbsp;mcg/ml at weeks 12, 24, and 48. These mean concentrations in patients with pediatrics plaque psoriasis were similar to the concentrations observed in patients with juvenile idiopathic arthritis (treated with 0.4&nbsp;mg/kg etanercept twice weekly, up to maximum dose of 50&nbsp;mg per week). These mean concentrations were similar to those seen in adult patients with plaque psoriasis treated with 25&nbsp;mg etanercept twice weekly.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the toxicological studies with Enbrel, no dose-limiting or target organ toxicity was evident. Enbrel was considered to be non-genotoxic from a battery of <em>in vitro</em> and <em>in vivo</em> studies. Carcinogenicity studies, and standard assessments of fertility and postnatal toxicity, were not performed with Enbrel due to the development of neutralising antibodies in rodents.</p><p>&nbsp;</p><p>Enbrel did not induce lethality or notable signs of toxicity in mice or rats following a single subcutaneous dose of 2000&nbsp;mg/kg or a single intravenous dose of 1000&nbsp;mg/kg. Enbrel did not elicit dose-limiting or target organ toxicity in cynomolgus monkeys following twice weekly subcutaneous administration for 4 or 26&nbsp;consecutive weeks at a dose (15&nbsp;mg/kg) that resulted in AUC-based serum drug concentrations that were over 27-fold higher than that obtained in humans at the recommended dose of 25&nbsp;mg.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sucrose</p><p>Sodium chloride</p><p>L-Arginine hydrochloride</p><p>Sodium phosphate monobasic dihydrate</p><p>Sodium phosphate dibasic dihydrate</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Shelf life: 3 years.
Do not use Enbrel after the expiry date which is stated on the carton after EXP:. The expiry date refers to the last day of that month.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C).</p><p>Do not freeze.</p><p>&nbsp;</p><p>Keep the pre-filled pens in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>50&nbsp;mg solution for injection in pre-filled pen</u></p><p>&nbsp;</p><p>Pre-filled pen containing a 50&nbsp;mg pre-filled syringe of Enbrel. The syringe inside the pen is made from clear type 1 glass with a stainless steel 27 gauge needle, rubber needle cover, and plastic plunger. The needle cap of the pre-filled pen contains dry natural rubber (a derivative of latex). See section 4.4.</p><p>&nbsp;</p><p>Cartons contain 2, 4 or 12 pre-filled pens of Enbrel with 2, 4 or 12 alcohol swabs. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Instructions for use and handling</u></p><p>&nbsp;</p><p>Before injection, Enbrel single-use pre-filled pens should be allowed to reach room temperature (approximately 15 to 30 minutes). The needle cover should not be removed while allowing the pre‑filled pen to reach room temperature. By looking through the inspection window, the solution should be clear to slightly opalescent, colourless to pale yellow or pale brown and may contain small translucent or white particles of protein.</p><p>&nbsp;</p><p>Comprehensive instructions for administration are given in the package leaflet (section 7 &quot;Instructions for use&quot;).</p><p>&nbsp;</p><p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MARKETING AUTHORISATION HOLDER

Pfizer Saudi Limited, Saudi Arabia

MANUFACTURED BY

Pfizer Manufacturing Belgium NV, Puurs, Belgium

PACKED & RELEASED BY

Pfizer Saudi Limited, King Abdullah Economic City, Saudi Arabia

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>